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Let the future tell the truth, and evaluate each one according to his work and
accomplishments. The present is theirs; the future, for which I have really
worked, is mine.
Nikola Tesla

ABSTRACT
Statins are a class of drugs used to treat hypercholesterolemia and to prevent
cardiovascular diseases. They belong to the so called HMG-CoA reductase in-
hibitors and inhibit cholesterol synthesis. By inhibiting an early step in choles-
terol synthesis, statins prevent neoformation of cholesterol in the liver and thus
reduce LDL cholesterol levels. The most adverse effects reported are muscle-
related adverse events and are generally described as myopathies. Myopathy
is a muscular disease, affecting skeletal muscles by destroying its structural in-
tegrity. The symptoms range from muscle weakness on to muscle cramps to
the point of disintegration of the striated skeletal muscle cells. This worst case
is termed as rhabdomyolyse and can lead to death if symptoms are not rec-
ognized. Because statins can damage and destroy muscle cells, statins are de-
fined as myotoxic. The exact mechanism how statins induce toxicity in muscle
cells still needs to be clarified. It is currently not known to full detail whether
cytotoxic effects originate at the plasma membrane or are initiated intracellu-
larly. This thesis deals with these two hypotheses and examines the role of
transport proteins in the statin-induced myotoxicity. Here the influence of the
transport proteins OATP1B1 and OAT1B3 on the viability of muscle cells after
statin treatment was investigated. These transporters are naturally expressed
in hepatocytes and known to be responsible for statin uptake into liver cells. To
identify the relevance of uptake transporters to the in vivo activity of statins,
an in vitro tool was established, which allows studying the influence of uptake
transporters on statin toxicity in muscle cells. Therefore, skeletal muscle cells
from rat (L6) and mouse (C2C12) were transfected with the with the hepato-
cellular statin transporter OATP1B1 or OATP1B3. Clones were screened with
a transport assay measuring the uptake of a model substrate into cells to iden-
tify a functionally active clone. The expression level of the transport proteins
in the transfected cells was investigated at the RNA and protein level using
qRT-PCR and confocal laser-scanning microscopy. Toxicity studies comparing
wild type and transfected cells investigated the susceptibility towards statins.
vii
Here, cell viability was assessed after cells were treated with statins at increas-
ing concentrations. These studies revealed no difference regarding statin toxi-
city comparing the two cell lines. Nevertheless, it was possible to demonstrate
an increased susceptibility of muscle cells towards statins compared to the non-
muscle cell line CHO. To assess statin-induced apoptosis, an assay was estab-
lished measuring caspase-3 activity after statin treatment. Here, it was pos-
sible to demonstrate that caspase-3 activity is already induced after six hours.
Caspase-3 activity in C2C12 OATP1B1 cells is increased in a statin concentration
dependent manner. This effect was not observed in the wild type cells, clearly
demonstrating that statin-induced myotoxicity is dependent upon a transmem-
brane transport mechanism. This thesis helped to better understand the mech-
anism of statin-induced myotoxicity. Further studies using human muscle cells
could identify the exact transport proteins, responsible for statin uptake and
thus could deliver an explanation why statins are toxic specifically for muscle
cells and why other tissues types are not affected.
viii
ZUSAMMENFASSUNG
Statine zählen zu den am meisten verschriebenen Medikamenten in der west-
lichenWelt. Sie dienen dazu die Hypercholesterinämie zu behandeln undHerz-
Kreislauf-Erkrankungen vorzubeugen. Statine gehören zu den Cholesterin-Syn-
these-Enzym-Hemmern vomTyp derHMG-CoA-Reduktase-Inhibitoren. Durch
Inhibition eines frühen Schrittes in der Cholesterinsynthese führen sie zu einer
Verminderung des LDL-Cholesterins, indem sie unter anderem dessen Neubil-
dung in der Leber hemmen. Jedoch haben Statine Nebenwirkungen, die nicht
zu vernachlässigen sind. Eine davon ist die Myopathie, welche die Skeletmus-
kulatur betrifft und hier zu funktionellen und strukturellen Veränderung führt.
Die Symptome reichen von Muskelschwäche über Muskelkrämpfe bis hin zur
Auflösung der quergestreiften Skelettmuskelzellen. Dieser schlimmst anzuneh-
mende Fall wird als Rhabdomyolyse bezeichnet, welche bei einem unerkannt
bleiben zum Tode führen kann. Da Statine die Muskelzellen schädigen und
zerstören werden sie als myotoxisch bezeichnet. Der genaue Mechanismus der
Statin-induzierten Moypathie ist bislang nicht vollständig aufgeklärt. So ist bis-
weilen unklar ob die Toxizität an der Zellmembran ausgelöst wird und durch
eine Signalkaskade in das Zellinnere weitergeleitet wird oder ob Statine ein in-
trazelluläres Ziel haben nachdem sie in die Zelle aufgenommen wurden, wel-
ches das Absterben der Muskelzelle verursacht. Diese Doktorarbeit beschäftigt
sich mit diesen beiden Hypothesen und untersucht die Rolle von Transportpro-
teinen in der Statin-induzierten Myotoxizität. Dabei wurde untersucht welchen
Einfluss die Transporter OATP1B1 und OATP1B3 auf die Viabilität von Mus-
kelzellen haben, nachdem diese mit Statinen behandelt wurden. Diese Trans-
porter sind natürlicherweise in Hepatozyten zu finden und sind erwiesener-
maßen für die Aufnahme von Statinen in die Leberzelle verantwortlich. Für
diese Untersuchungen wurden ein in-vitro-Tool generiert und anschliesend To-
xizitätsstudien durchgeführt. Dafür wurden dieMyoblastenzelllinien von Ratte
(L6) und Maus (C2C12) jeweils mit den humanen Transportern OATP1B1 oder
ix
OATP1B3 transfiziert. Um einen Klon zu finden der funktionell aktiv ist wur-
den diese mit einem zellbasierten Transportexperiment gescreent, bei dem die
Aufnahme eines Modellsubstrats in das Zellinere gemessen wurde. Zusätzlich
wurde das Expressionsniveau der Transportproteine mittels quantitativer real-
time PCR bestimmt. Nachdem ein funktionaler Klon gefunden werden konnte,
wurde dieser mittels Western Blot Technologie und konfokaler Laser-Scanning-
Mikroskopie charakterisiert. In den Toxizitätstudien wurde untersucht, ob die
transfizierten Zellen empfindlicher gegenüber Statinen sind. Dazu wurden die
Zellen mit Statinen über ein breites Konzentrationsspektrum behandelt und an-
schließend die Zellviabilität bestimmt. Bei diesen Studien konnte kein Unter-
schied zwischen den beiden Zelllinien hinsichtlich der Toxizität von Statinen
festgestellt werden. Es konnte aber nachgewiesen werden, dass Muskelzellen
empfindlicher gegenüber Statinen sind, als die Fibroblastenzelllinie CHO. Dar-
aufhin wurde ein Versuchsaufbau etabliert der mittels Caspase-3-Aktivität die
Induktion von Apoptose durch Statine messen kann. Hier zeigte sich bereits
nach einer Statinbehandlung von sechs Stunden, dass in OATP1B1 exprimie-
renden Zellen mit zunehmender Statinkonzentration eine steigende Caspase-
3-Aktivität zu messen war. Diese Konzentrationsabhängigkeit konnte in den
Wildtypzellen nicht nachgewiesen werden. Dieser Versuch zeigte deutlich, dass
die Statin-induzierte Mytoxizität von einem transmembranären Transportme-
chanismus abhängt. Mit dieser Arbeit wurde dazu beigetragen, den Mechanis-
mus der Statin-induzierten Myotxizität besser zu verstehen. Weitere Untersu-
chungen an humanen Muskelzellen könnten den genauen Transporter identi-
fizieren, der für die Aufnahme von Statinen verantwortlich ist und somit eine
Erklärung liefern warum Statine spezifisch für Muskelzellen toxisch sind und
warum andere Gewebetypen nicht betroffen sind.
x
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1 INTRODUCTION
1.1 Statins
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or
statins, are a class of drugs used for the treatment of hypercholesterolemia.
Statins lower serum cholesterol levels and thereby significantly reduce the risk
of cardiovascular events [1]. HMG-CoA reductase inhibitors act at the rate lim-
iting step of the cholesterol synthesis by competitively inhibiting the enzyme
HMG-CoA reductase and thus reducing the mevalonate production rate, which
is the next molecule in the cholesterol synthesis cascade. During cholesterol
synthesis a broad range of products in addition to cholesterol are generated,
such as coenzyme Q10, dolichol and heme A [2], which have an essential role
in cell physiology and maintenance of proper cell function.
All statins currently on the market possess a HMG-like moiety with an open
lactone ring (i.e. mevalonate), except of simvastatin and lovastatin, which have
a closed lactone ring. The closed ring structure is transformed into the biolog-
ically active form with an open ring in the body by hydrolysis. Newer statins
are administered as the open acid forms and have a higher affinity for HMG-
CoA reductase and consequently possess higher potency of inhibition. This
high affinity for HMG-CoA is shown by enzyme activity assays, where inhibi-
tion constants (Ki) are between 5–45 nM while the Michaelis constant (Km) of
HMG-CoA is 4 µM, explaining the potent inhibition of this enzyme by statins
including simvastatin, pravastatin, fluvastatin, cerivastatin, atorvastatin and
rosuvastatin [3–5].
The pathway of cholesterol synthesis is presented in Fig. 1. The reaction cat-
alyzed by HMG-CoA reductase is the rate-limiting step of cholesterol biosyn-
thesis. HMG-CoA reductase is subject to feedback-inhibition by cholesterol.
1
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Hence, inhibiting this enzyme reduces cholesterol levels. To maintain the in-
tracellular cholesterol level, LDL-receptors are transcriptionally up regulated,
which in turn leads to a decreased level of serum cholesterol. The consequently
increased uptake of extracellular cholesterol into hepatocytes does interestingly
not lead to higher cholesterol levels in the liver cells. Reason for this is the liver
specific cholesterol hydroxylase (CYP7A1), which catalyzes the first step in the
biosynthesis of bile acids. This process of cholesterol degradation in the liver
leads to an overall reduction of cholesterol in the whole body. As more than
50% of total body cholesterol is endogenously produced, with the major site of
synthesis being the liver, the target organ of statins is the liver [6].
Fig. 1: Pathway of cholesterol biosynthesis.
HMG-CoA reductase converts HMG-CoA to mevalonate. Inhibition of
this enzyme leads not only to reduced cholesterol levels, but also
inhibits intermediate products like farnesyl pyrophosphate and
geranylgeranyl pyrophosphate which are crucial to modify the
functions of some small GTPases (adapted from [7, 8]).
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1.1.1 Statin-induced myopathies and rhabdomyolysis
Although statins belong to the best selling drugs dispensed by prescription in
the US [9] and have an advantageous safety profile [10], they show some side ef-
fects which cannot be neglected. The most adverse effects reported are muscle-
related adverse events (AEs) and are generally described as myopathies in the
clinics [11]. The most common type of statin-induced myopathies is myalgia,
which leads to muscle pain, fatigue, and weakness without elevated creatine
kinase (CK) levels. AEs characterized by muscle symptoms with increased CK
levels less than 10 times the upper limit of normal (ULN) are denoted as myosi-
tis. A serious, but rare AE under statin treatment is rhabdomyolysis (rhabdo:
rod-like structures, myo: muscle, and lysis: dissolution) with an incident of 3.4 per
100,000 patient years [11]. Rhabdomyolysis is associated with muscle symp-
toms, elevated CK levels >10 times ULN and with creatinine elevation which
involves usually brown urine and urinary myoglobin [12]. Rhabdomyolysis is
the rapid breakdown of skeletal muscle tissue that leads to a release of break-
down products like myoglobin into the blood stream. Normally, myoglobin
is loosely bound to plasma globulins and only small amounts are filtered in
the kidney. When massive amounts of myoglobin are released, the binding ca-
pacity of the plasma protein is exceeded and myoglobin is then filtered by the
glomeruli and reaches the tubules of the kidney. In the tubules myoglobin can
form solid aggregates, called urinary casts, which reduce the flow of fluid and
finally block the tubules. Additionally, the heme-bound iron can be released
and generate reactive oxygen species damaging kidney cells. These processes
lead to destruction of renal tubular cells, which reduces the glomerular filtra-
tion rate and finally lead to dysfunction of the kidney termed as kidney failure.
To develop rhabdomyolysis patients have to be on statin for about one year in
average, but there are cases reported where patients develop rhabdomyolysis
already after only a few months depending on patients risk factors and further
medications [13].
1.1.2 Patient related risk factors
Certain precipitating factors and predisposing conditions are known to increase
the chance to develop rhabdomyolysis under statin treatment such as increased
age, female gender, renal insufficiency, hepatic dysfunction, hypothyroidism,
INTRODUCTION 4
and several metabolic muscle diseases [8, 14–16]. Most of them promote my-
opathy by altering the metabolism and increasing the bioavailability of statins
leading to higher plasma levels. The cytochrome p450 (CYP) system is a group
of enzymes distributed ubiquitously. Its members are monoxygenases and add
often a functional group to poorly water soluble drugs. This allows conjugation
of such drugs to hydrophilic groups, which results in a conversion to more wa-
ter soluble metabolites to facilitate biliary or renal excretion. All statins except
of pravastatin utilize the CYP system for metabolism and disposal. A genetic
predisposition with decreased activity of CYP3A4 reduces intrahepatic statin
metabolism and consequently results in higher plasma concentrations [17, 18].
Membrane transporters being responsible for uptake (e.g. OATPs) and excre-
tion (e.g. multidrug resistance-associated protein 2 [MRP2]) of substances play
an important role in drug disposition and are recognized as important determi-
nants of the transmembrane passage of drugs, not only in the liver. In hepato-
cytes, OATPs mediate the uptake of statins from the sinusoidal blood plasma.
A polymorphism in the SLCO1B1 gene (c.521T>C, p.Val174Ala) was found to
be highly significantly associated with myotoxicity in patients on a high dose
simvastatin regimen [19]. This OATP1B1 variant displays in vitro a reduced
transport capacity [20] and consequently affects the pharmacokinetics of statins
by increasing its area under the curve (AUC) and the maximum serum concen-
tration cmax [21, 22].
1.1.3 Statin related risk factors
The risk of developing myopathies is also depending on the statin itself. Hy-
drophilic statins like pravastatin and rosuvastatin have lower chance to enter
non-hepatic tissues compared to lipophilic statins like lovastatin, simvastatin,
fluvastatin, atorvastatin and cerivastatin andmay therefore be theoretically less
toxic to myocytes. Still, there is an ongoing debate whether different statins
have distinct risks of inducing myotoxicity [22]. The lowest risk to develop AEs
is associated with fluvastatin, while atorvastatin shows the highest risk identi-
fied by meta-analysis of 18 prospective randomized controlled trials; the risks
for simvastatin, lovastatin and pravastatin were intermediate and comparable
[23]. In 2001 the hydrophilic cerivastatin was withdrawn from the market be-
cause of 52 deaths linked to cerivastatin-induced rhabdomyolysis that lead to
kidney failure. The risk was found to be higher among patients who received
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gemfibrozil concomitantly or the full dose of cerivastatin (0.8 mg/day). Rhab-
domyolysis was 10 times more common for cerivastatin compared to the other
five statins on the market at this time [24].
1.1.4 Role of comedications in statin-induced myopathies
The risk of developing myopathy during statin treatment is increased if pa-
tients are co-treated with certain other drugs like cyclosporine A, gemfibrozil
and possibly some other fibrates which can reduce the time to develop rhab-
domyolysis down to one month [14, 25]. As statins are substrates of the CYP
isoenzyme system, a concomitant treatment with inhibitors of this enzyme (e.g.
cyclosporine, the antidepressant nefazodone, macrolide antibiotics, or protease
inhibitors to treat HIV) increases the risk of myopathy with statins [26]. By
competitively inhibiting the CYP-system, the metabolism of statins is reduced,
leading to increased plasma levels and greater risk of AEs. As pharmaceutical
products are often substrates or inhibitors of transporters, a second possibility
to influence to plasma concentrations is the transporter mediated drug-drug
interaction. Co-administrated drugs can reduce hepatic uptake of statins by
acting as competitive inhibitor with higher affinity for the active site of the rel-
evant transporter [27]. Many drugs, e.g. cyclosporine or gemfibrozil have been
identified to inhibit drug transporters like OATP1B1, and thereby markedly in-
crease the plasma concentrations and exposure of statins [28].
Myopathy and rhabdomyolysis is restricted to skeletal muscle tissue, and car-
diomyopathy has never been associated with statin treatment. Discontinuation
of the therapy leads to recovery of patients with variable improvement. While
one study showed consistent recovery of statin muscle AEs [29], Vladutiu et.
al found that “. . . variable persistent symptoms occurred in 68% of patients despite
cessation of [statin] therapy” [30]. Interestingly, myopathy can be prevented in
a rat model by administering mevalonate, the product of the inhibited enzy-
matic reaction, supporting the concept that this toxicity is a direct result of
cholesterol synthesis inhibition and not an off-target effect [25]. Krähenbühl et.
al showed that even geranylgeraniol, which is produced further down in the
cholesterol synthesis pathway, can prevent statin-induced cytotoxicity, when
co-administrated with simvastatin using a C2C12 myotube model [31]. One
the other hand, inhibition of squalene synthase and squalene epoxidase did
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not induce myotoxicity in primary cultures of rat myotubes [32, 33], and squa-
lene itself cannot rescue from myotoxicity, when co-administrated with statins
[31]. Both enzymes are part of the squalene branch at the distal end of choles-
terol biosynthesis and catalyze metabolic steps uncoupled of isoprene synthe-
sis. Taken together, myotoxicity is not directly induced by lower cholesterol
levels, but due to the reduction of the availability of the isoprenoids geranyl-
geranyl pyrophosphate (GG-PP) and farnesyl pyrophosphate (F-PP), which are
byproducts of the cholesterol synthesis pathway.
1.1.5 Putative molecular mechanisms of statin toxicity
The exact mechanism of statin-induced myotoxicity is not fully understood,
despite 26 years after it was reported for the first time [34]. Several mecha-
nisms are suggested for example perturbed N-linked glycosylation, impaired
isoprenylation, disruption of selenoprotein synthesis, impaired function of skele-
tal muscle mitochondria, increased excitability of muscle cell membrane, and
impaired calcium signaling [7, 35–37].
Perturbed N-linked glycosylation
N-linked-glycosylation is a covalent modification that proteins undergo dur-
ing and after translation. It is an integral component for proper trafficking
and functioning of numerous proteins, especially for proteins localized in the
plasmamembrane such as receptors and transporters. Dolichols are polyprenols
containing 16 to 22 isoprene units and mediate the N-linked glycosylation of
nascent polypeptides by serving as carriers, as well as an anchor whereupon
the core oligosaccharide unit for protein glycosylation is assembled. N-linked-
glycosylation is dependent on themevalonate pathway, since dolichols are deriva-
tives of G-PP (Fig. 1). Reduced dolichol production by statins can impair gly-
cosylation and can therefore culminate in decreased membrane expression of
specific receptors or membrane associated glycoproteins such as dystroglycan
which undergoes extensive post-translational modification. Dystroglycan fa-
cilitates communication between muscle cytoskeleton and extracellular matrix,
which can be interrupted, when dystroglycan glycosylation is defective [8, 35,
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38]. However, no study so far investigated the direct effect of statins on dystro-
glycan glycosylation.
Statins can also impair insulin-induced glucose uptake as a consequence of
reduced expression of glycosylated insulin receptor and insulin-like growth
factor-1 (IGF-1) receptor at the plasma membrane and accumulation of ungly-
cosylated receptors in endoplasmic reticulum as shown in mouse C2C12 my-
oblasts [39]. Moreover, reduced IGF-1 signaling leads to induction of atrogin-
1, which is a hallmark of muscle atrophy. Atrogin-1 is expressed in a tissue-
specific manner and appears to be a critical component in the enhanced pro-
teolysis leading to muscle atrophy in diverse diseases. A recent study used
C2C12 myotubes and zebrafish to show that depletion of geranylgeranyl after
lovastatin treatment results in atrogin-1 induction [40].
Impaired isoprenylation
Isoprenoids, also called terpenes, like geranylgeranyl-PP and F-PP are organic
substances, composed of at least two isoprenes which have a characteristic five
carbon structure. Modification of proteins by covalent addition of isoprenoids
to conserved cysteine residues is called prenylation and promotes membrane
interactions with several proteins like nuclear lamins, guanosine triphosphate
(GTP)-binding proteins (G-proteins), the subunits of trimeric G-proteins or pro-
tein kinases. In addition prenylation plays a major role in several protein-
protein interactions [41]. Prenylated G-proteins such as Rab, Ras and Roh play
crucial roles in signaling pathways controlling cell growth and differentiation,
e.g. metabolic control of the cytoskeleton is also mainly depending on coordi-
nated signaling through G-proteins [35]. One study showed that statin treat-
ment of L6 myoblasts leads to induction of apoptosis initiated by depletion of
membrane bound Ras [42]. Recent studies investigating the role of Rab small
GTPases showed that statin treatment of isolated rat skeletal myofibers lead to
inactivation of Rabs and induced vacuolation of the myofibers, degeneration
and swelling of organelles, and eventually apoptosis [43].
Lamins are important structural proteins interact with membrane-associated
proteins from the inner nuclear membrane. They are involved in chromatin
organization, gene expression, and play amajor role duringmitosis by breaking
down and reforming the nuclear envelope. Several lamins need to undergo
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farnesylation [44]. Lovastatin was previously shown to inhibit iosprenylation
of lamin A and prevented consequently the assembling process of lamin A into
the inner nuclear membrane [45]. This could possibly lead to a fragile nucleus
with a deranged nucleoskeleton unresistant to forces occurring during muscle
contraction. Furthermore it was shown that transcription of genes activated
by mechanical stress (e.g. Nf-κB) is impaired [46], leading to the assumption
that defective lamin prenylation induced by statins may indeed underlie statin-
associated myopathy.
Selenoproteins
Selenoproteine are proteins containing a selenocystein amino acid residuewhich
is inserted by a specific tRNA during protein synthesis. Selenocystein (Sec)
tRNA is encoded by UGA, which normally represents the stop codon. If the
UGA containing area of the mRNA forms a stem-loop structure, the stop codon
is skipped and selenocystein can be inserted during translation into the matur-
ing protein. Sec-tRNA also needs to undergo isopentylation and the absence
of isopentylated tRNA could result in improper translation by inserting a stop
codon instead of Sec. This may lead to premature termination of translation and
production of truncated, nonfuctional proteins. A recent study investigated the
isopentenylation of selenocysteine tRNA in selenoprotein synthesis after in vivo
statin treatment. Most cellular selenoproteins investigated were reduced, some
of them more than 90% [47]. Truncated proteins were found in large amounts,
due to the premature abortion of translation, and were rapidly degraded.
Mitochondria
Ubiquinone (CoQ10) is an isoprenoid which plays an important role as electron
transporter in the mitochondrial respiratory chain and supports ATP synthe-
sis. CoQ10 is dissolved in the hydrophobic region of the inner membrane of
mitochondria. It can move freely within the hydrophobic region of the mem-
brane by passive diffusion, where it acts as a mobile electron carrier of the
electron-transport chain. CoQ10 collects reducing equivalents from the less mo-
bile NADH-Q reductase and passes them onto the cytochromes further down-
stream the respiratory chain. Reduction of CoQ10 is known to impair mito-
chondrial function and hence contributing to the development of myopathies.
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As statins block the intracellular CoQ10 synthesis, it is reasonable that statin-
induced CoQ10 reduction is hypothesized to participate in statin-associated
myopathies [48]. Krähenbühl et al. showed that statins are mitochondrial tox-
ins affecting the electron transport chain. The group used isolated rat skeletal
muscle mitochondria and a rat skeletal cell line (L6) to show that lipophilic
statins decrease the mitochondrial membrane potential, induce mitochondrial
swelling, impair mitochondrial β-oxidation, uncouple oxidative phosphoryla-
tion, and finally induce apoptosis [37]. On the other hand statins did not reduce
CoQ10 levels in skeletal muscle cells (except of high dose simvastatin treat-
ment), although they are shown to reduce CoQ10 serum levels [48]. Still, the
role of CoQ10 in statin associatedmyopathies is unclear and a direct association
between reduced intramuscular CoQ10 levels andmitochondrial myopathy has
not been conclusively shown [48]. It seems more likely that CoQ10 is a critical
predisposing factor, especially for patients with other CoQ10 reducing condi-
tions, and does not appear to be the main cause of statin-induced myopathy
[48].
1.1.6 Molecular targets of adverse statin effects
Taken together, the discussedmechanisms of statin myotoxicity are highly com-
plex because the list of potentially affected intermediates, particularly those of
isoprenoid metabolism, is quite large. Furthermore, it is still unclear whether
statins need to be taken up into muscle cells or whether they can act from the
plasma membrane to unveil their toxic potential. Currently the following two
hypotheses are under discussion how statins initiate myopathies. To induce
myopathies from outer cell, statins need to bind or interact with components
of the cell membrane to transmit the signal across the membrane into the cell.
The second hypothesis claims that statins need to be transported across the cell
membrane to become toxic from inside the cell. Evidence for this concept is
given by the fact that not only lipophilic statins but also the hydrophilic pravas-
tatin can induce myopathies [49]. It is hard to conceive that lipophilic statins
can enter muscle cells without a transport mechanism. Indeed it is doubtful,
whether passive diffusion of drugs across plasma membranes exists at all [50].
The group of Endou et al. was the first group to show the expression of a poten-
tial statin transporter in human skeletal muscle, namely OAT1 and OAT3 [51].
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They further demonstrated the uptake of pravastatin via OAT3 in a heterolo-
gous expression system.
In 2008 Sakamoto et al. demonstrated the expression of the uptake transporters
Oatp1a4 and Oatp2b1 in rat skeletal myofibers but not in satellite cells and fi-
broblasts. They found that pravastatin induces cell death only in myofibers
and not in satellite cells and fibroblasts, supporting the importance of the statin
transporters. They further demonstrated that concomitant treatment with the
OATP substrate ES3 prevented cell death, which was not the case when cells
were co-incubatedwith theOAT substrate PAH (p-aminohippuric acid) strength-
ening the evidence that Oatps are involved in pravastatin uptake intomyofibers
[52]. Recently Knauer et al. demonstrated the expression of OATP2B1 on the
sarcolemmal membrane of human skeletal muscle fibers [53]. The same group
also showed that transfection of OATP2B1 into human skeletal muscle my-
oblasts increases intracellular accumulation and toxicity of rosuvastatin and
atorvastatin in these cells [53]. These recent studies increase the awareness
that transport proteins might play a more important role in statin-induced my-
opathies than hitherto expected. Further in vivo and in vitro studies are still
needed to better understand statin-induced pathophysiological mechanisms in
muscle and the role of transport proteins.
1.2 Transport proteins
The target organ of statins is the liver. Therefore, it is essential that a high pro-
portion of the oral administered drug enters the hepatocyte, which is facilitated
by protein mediated transport. In the last years drug transporters have been
recognized more and more to be important for drug discovery and develop-
ment as they function as gatekeepers enabling the uptake and efflux of ther-
apeutic substances and endogenous agents into and out of cells, and thereby
play a major role for absorption, distribution, and excretion of endogenous
compounds and drugs [54, 55]. Based on their mechanism of function, trans-
porters can be divided into active and passive transporters. Active transporters
can establish a concentration gradient of solutes or ions across a membrane by
using diverse energy-coupling mechanisms. They can be further divided into
primary- or secondary-active transporters. Primary-active transporters utilize
metabolic energy like ATP to transport molecules across a membrane. ABC
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(ATP-binding cassette) transporters andATPases belong to the class of primary-
active transporters and translocate solutes or ions out of the cell or into cell or-
ganelles. Secondary-active transporters utilize the established and maintained
electrochemical gradient of primary-active transporters as energy resource by
ion-coupling to translocate nutrients against their concentration gradient across
a membrane.
Facilitated transporters are passive transporters allowing the diffusion of so-
lutes down their electrochemical gradient across a membrane with a fixed num-
ber of solutes per translocation cycle. Channels are similar to passive trans-
porters. Here, the flow of solutes or ions is controlled by a gating mechanism
and follows the electrochemical gradient. The rate of transport is much faster
compared to passive transporters and is depending on the concentration of ions
or solutes and the membrane potential. The conductance of a channel is de-
pending on the surrounding milieu or on a directed signal which determines
the open probability of the channel.
1.3 OATPs
1.3.1 Nomenclature
The organic anion transporting polypeptides (rodent: Oatps; human: OATPs)
are a class of influx transport proteins within the SLC superfamily. Based on
phylogenetic features, the nomenclature of its members was standardized and
updated in 2004, and the originally named SLC21A superfamily was renamed
to SLCO (Solute carrier family of the OATPs) [56]. So far more than 300 mem-
bers of the OATP/SLCO superfamily have been identified, thereof 11 expressed
in humans, which are classified into six families based on their similarity of the
amino acid sequence [57].
The first member of OATP superfamily was isolated and cloned by Jaquemin et.
al in 1993 from rat liver by using expression cloning in Xenopus laevis oocytes
[58] and was shown to have properties of a sodium independent organic an-
ion transporter. The first human OATP (now called OATP1A2) was isolated
by Kullak-Ublick et. al [59] from human liver but shows highest expression in
cerebral capillary endothelial cells of the blood-brain barrier [60]. While most
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OATPs/Oatps are expressed in multiple tissues, including the liver, kidney, in-
testine, blood-brain barrier, choroid plexus, placenta, lung, testes and heart,
some are selectively expressed in certain tissue like OATP1B1 and -1B3 (both in
the liver).
1.3.2 Substrate specificity
OATPs/Oatps mediate transport of numerous endogenous and exogenous sub-
stances across the cell membrane in a ATP- and sodium-independent manner
[57]. In general, substrates are amphipathic molecules with molecular weights
greater than 350 Daltons [56]. OATPs facilitate the uptake of a broad range
of substrates including steroid conjugates, bile acids, thyroid hormones, lin-
ear and cyclic peptides as well as numerous xenobiotics including mushroom
toxins, antibiotics, sartans, statins and anticancer drugs. Numerous substances
are transported by several OATPs, like estrone-3-sulfate (E3S), estradiol-17β-
glucuronide (E17βG) or bromosulphophthalein (BSP), which makes them use-
ful model substrates. Recent investigations indicate that OATPs have multiple
substrate binding sites. For OATP1B1 it has been shown to have a biphasic
saturation kinetic for E3S, suggesting the presence of both a low-affinity, high-
capacity binding site and a high-affinity, low-capacity binding site. Depending
on the substrate used, inhibition studies have shown that compounds can have
inhibitory, stimulatory or no effect on OATP-mediated transport [61, 62].
Recent studies show that OATPs can perform transport in both directions and
that theywork as electroneutral exchangers. Leuthold et al. showed that OATP/-
Oatp substrate transport generally leads to stimulation of bicarbonate efflux,
which supports the concept that OATPs/Oatps act as anion exchangers [63].
Furthermore, pH can affect the efficacy of substrates transported via OATPs.
Acidic extracellular environment in general stimulates transport activity of OATPs/-
Oatps [25]. The authors further suggest that the pH dependent transport is
linked to a highly conserved histidine in the third transmembrane domain. This
area is also involved in altered transport properties of polymorphic OATPs [25].
OATP2B1 has been shown to increase transport activities under acidic condi-
tions caused by higher substrate affinity [64]. The reason for this phenomenon
can be explained by the protonation of a conserved histidine residue at the ex-
tracellular end of transmembrane domain three. Being also expressed in the
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small intestine, OAPT2B1 can thus facilitate the absorption of clinically relevant
drugs due to increased transport and wider range of substrates [65].
1.3.3 Structure
All OATP/Oatp family members share a very similar topology. Based on com-
putational analyses they consist of 12 transmembrane domains with a large ex-
tracellular loop five, harboring the C- and N-treminal end inside the hepatocyte
(Fig. 2). Meier-Abt et al. presented for the first time a three dimensional struc-
Fig. 2: Structure of OATP1B1
Topological scheme of the secondary structure of OATP1B1, showing
the 12 transmembrane domains and known single nucleotide
polymorphisms (SNPs). Adapted from [28].
tural model for all OATPs/Oatps where they propose that OATPs/Oatps func-
tion in a rocker-switch type of transport mechanism [56] . In this mechanism,
the transport protein is believed to have two major alternating conformations:
inward-facing and outward-facing. Here, the substrate is translocated through
a central, positively charged pore, which is a common and likely to be a con-
served feature of all OATPs/Oatps and functionally significant. However, the
exact identification of a substrate binding site and other sites critically involved
in substrate translocation requires further studies to reveal the exact mechanism
of substrate transport.
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1.3.4 The hepatocellular OATPs 1B1 and 1B3
The hepatocyte-specific OATP1B1 (SLCO1B1) andOATP1B3 (SLCO1B3) aremul-
tispecific organic anion transporting proteins exhibiting an amino acid sequence
identity of 80%. They are localized at the sinusoidal membranes and medi-
ate the influx of their substrates from sinusoidal blood plasma into hepato-
cytes. Thus, they represent an important step in clearance of clinically rele-
vant drugs by metabolism or biliary excretion. Both proteins mediate trans-
membrane transport of endogenously synthesized substances including bile
salts like cholate, glycocholate and taurocholate [66], conjugated steroids like
E17βG, E3S, dehydroepiandrosterone sulfate (DHEAS) [67] and other organic
ions like BSP and bilirubin [68, 69]. Besides endogenously synthesized sub-
stances OATP1B1 and -1B3 mediate hepatocellular uptake of a variety of dif-
ferent drug substrates like methotrexate, rifampicin and several statins [66, 67].
Both OATPs have been identified to be the major player in hepatocellular up-
take of statins, besides OATP2B1, as they mediate the hepatocellular-uptake
of almost all statins [67, 68]. For OATP1B1 several polymorphisms have been
described [70] and a genome-wide association study linked SLCO1B1 polymor-
phisms to an increased risk of statin-induced myopathy [71], thereby support-
ing the important role of OATP1B1 in the hepatic uptake and elimination of
statins and possibly of other drugs.
1.4 Cell systems to study statin toxicity
Skeletal muscle consists of multi-nucleatedmuscle cells calledmyofibers, which
have a long cylindric shape. Myofibers arise during myogenesis from several
undifferentiated myoblasts by cell to cell membrane fusion. During develop-
ment, embryonic progenitor cells enter differentiation phase and initiate with-
drawal from the cell cycle. These cells are called myoblasts and start to ex-
press various genes encoding structural proteins soon after initiation of differ-
entiation. Myoblasts can then fuse with one another to form a nascent multi-
nucleated myofiber [72]. Myoblast fusion is a fundamental step in the differ-
entiation of muscle and is initiated by muscle specific gene expression and fa-
cilitated by glycoproteins called cell-cell fusogens [73, 74]. The nascent my-
ofiber undergoes further maturation by increasing size, which requires further
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cell fusion with myoblasts or other myofibers and the expression of contrac-
tile proteins [74]. In vitro, myofibers are called myotubes, due to their tubu-
lar shape. The possibilities of investigating statin-induced myotoxicity encom-
passes a wide range of in vitro tools. The fundament of these tools is always
built by tissue explants, primary cells, or immortalized cell lines obtained from
various sources like human donors or rodents. Bischoff et al. successfully iso-
lated single live muscle fibers from the flexor digitorum brevis (FDB) of adult
rats and thereby created an in vitro system where the physical association be-
tween the myofiber and its stem cells is preserved [75]. Skeletal muscles are
composed of multinucleated myofibers with a length of several centimeters
which makes it difficult to culture them ex vivo. Myoblasts acquired primarily
from skeletal muscles permit a reasonable alternative. Already in 1968, Yafee
described a method how to extract myogenic cells from thigh muscle of new-
born rats, nowadays known as L6 myoblasts [76]. A few years later the same
group isolated myoblasts from thigh muscles of newborn mice, today known
as C2C12 myoblasts [77]. Cells of both myogenic cell lines are able to fuse and
form long and multinucleated myotubes under appropriate culture conditions,
representing an in vitromodel of myofibers. Thus, L6 as well as C2C12 provide
an excellent model to study muscle related questions. It is also possible to iso-
late muscle cells from humans. Primary human skeletal muscle cells (SkMC)
are isolated from different skeletal muscles from adult donors. New skeletal
muscle cells originate from quiescent satellite cells, which are located in the
muscle fibers between the basal lamina and the sarcolemma. Quiescent satellite
cells are activated by stimuli such as muscle damage. After activation, the cells,
now called myoblasts, start to proliferate and fuse with damaged muscle fibers
or with one another forming new myotubes.
Yet another possibility to investigatemuscle related issues is given by tumor cell
lines derived from human rhabdomyosarcoma (RMS). RMS is a neoplasm aris-
ing from skeletal muscle precursor cells (myoblasts) and is the most common
soft tissue sarcoma in children. Of the two major subtypes of RMS, embryonal
and alveolar, currently 30 cell lines are described in the literature (18 embry-
onal, 12 alveolar) [78]. One of the most commonly used cell line is RD and is
derived from a 7-year-old girl with a pelvic RMS [79].
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1.5 Aims of the presented work
The overall aim of the thesis was to investigate the mechanism how statins in-
duce toxicity in muscle cells. More precisely, the aim was to distinguish be-
tween statin-induced myotoxicity originating at the plasma membrane of mus-
cle cells from events occurring intracellular after uptake of statins.
As a first step we aimed to study the role of OATPs in statin-induced cellular
damage in non-muscle cells. The already established fibroblast cell line CHO,
expressing the human transporters OATP1B1, -1B3, or -2B1 was used to eluci-
date the toxic potential of different statins and to investigate whether the sus-
ceptibility against statins varies between the CHO cell lines expressing different
OATPs and the wild type.
Second, we aimed to establish a cell line stably expressing a membrane trans-
porter of the OATP family, responsible for statin uptake in human hepatocytes.
Therefore, a rat (L6) and a mouse (C2C12) skeletal muscle cell line was trans-
fected with OTAP1B1 or OATP1B3 cDNA. These new cell lines were used to
discriminate between extracellular and intracellular toxicity of statins.
The third aim was to investigate the capability of statins to induce apoptosis
by measuring caspase-3 activity after statin treatment. The new established cell
lines were compared to the non-transfected cells to elucidate the role of a statin
carrier in statin-induced apoptosis.
2 MATERIALS AND METHODS
2.1 Materials
All chemicals were of the highest degree of purity available from commer-
cial sources. Caspase-3 substrate Ac-DEVD-AMC was obtained from Bachem
(Bubendorf, Switzerland). Fetal calf serum (FCS) was US-origin und purchased
from Life TechnologiesTM(Carlsbad, CA, USA). Atorvastatin calcium trihydrate,
cerivastatin sodium, pravastatin sodium, rosuvastatin calcium and simvastatin
were obtained from LKT Laboratories, Inc. (St. Paul, MN, USA). [3H]-Estrone-
3-sulfate (45.0Ci/mmol) was obtained fromPerkinElmer (Waltham,Massachusetts,
USA). Cerivastatin [3H(G)] sodium salt (5.0Ci/mmol), pravastatin [3H(G)] sodium
salt (5.0Ci/mmol), simvastatin lactone [3H(G)] (5.0Ci/mmol) were obtained
from American Radiolabeled Chemicals, Inc. (St. Louis, MO, USA). Chinese
hamster ovary (CHO) cells expressing OATP1B1, OATP1B3 or OATP2B1 and
control cells were available in the lab and have been previously described [61,
80]. L6 and C2C12 cells were a kind gift from Prof. Stephan Krähenbühl,
Clinical Pharmacology & Toxicology, University Hospital Basel. Primary an-
tibodies recognizing OATP1B1 or OATP1B3 were available in the lab and have
been described earlier [81]. Primary antibody recognizing the middle region
of OATP1B1 was obtained from Aviva Systems Biology (San Diego, CA, USA).
Primary mouse monoclonal antibody recognizing the N-terminus of OATP1B1
was obtained from Creative Diagnostics (Shirley, NY, USA). Secondary anti-
body Alexa Fluor R©488 goat anti-rabbit IgG (H+L) was obtained fromMolecular
Probes (Eugene, OR, USA). Secondary antibody goat anti-rabbit IgG horseradish
peroxidase was obtained from GE healthcare (Buckinghamshire, UK).
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2.2 Methods
2.2.1 Cell culture
CHOwild type cells were grown inDulbecco’smodified Eagle’smedium (DMEM)
at low glucose levels (1 g/L) supplemented with 10% FCS, 2mM L-Glutamine,
100U/ml penicillin and 100µg/ml streptomycin and 50µg/ml L-proline at 37◦C
with 5%CO2 and 95% humidity. CHO cells expressing OATP1B1, OATP1B3
or OATP2B1 [61, 80] contained additionally 500µg/ml G-418 sulfate. L6 and
C2C12 cells were grown in DMEM at high glucose level (4.5 g/L) supplemented
with 10% FCS, 4mM L-Glutamine, 12.5mM HEPES (4-(2-hydroxyethyl)-1-pi-
perazineethanesulfonic acid). Medium to culture L6 and C2C12 cells express-
ing OATP1B1 or OATP1B3 contained additionally 500µg/ml G-418 sulfate and
will be termed as selection medium in the text later on.
2.2.2 Differentiation of myoblast into myotubes
To differentiate L6 and C2C12 cells from myoblasts into myotubes, cells were
treated for at least five days but no longer than 20 days with differentiation
medium with or without Insulin (9.5-10.5mg/mL). For differentiation DMEM
medium at high glucose level was used (4.5 g/L) supplemented with 2% Horse
serum, 4mM L-Glutamine, 12.5mMHEPES. Mediumwas exchanged every 2-3
days.
2.2.3 Transfection
2.2.3.1 Killing curve
A cell survival assay using alamarBlue R©with L6 and C2C12 wild type cells
was performed to obtain a killing curve. Cells were seeded in 48-well plates
with 2000 cells per well and incubated at 37◦C and 5%CO2. After 24 h the
medium was exchanged by medium containing the proper G418 concentration
(Tab. 2). Medium was exchanged periodically on the 3rd, 5th, 7thand 11thday.
Cell viability was measured at day 11 by adding 30µl (10% of total volume) of
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alamarBlue R©to everywell and cells were incubated at 37◦C for 4 h. Fluorescence
was measured using the plate reader “Twinkle LB970” (Berthold Technologies,
Bad Wildbad, Germany) with excitation wavelength of 560 nm and emission
wavelength of 590 nm. The lowest concentration that kills 100% of the wild
type cells was chosen to treat cells after transfection. Data were analyzed using
a four parameter logistic nonlinear regression model.
Tab. 2: Concentrations of G-418 used to obtain a killing curve for L6 and
C2C12 cells.
2.2.3.2 Preparation of the expression vector
The expression plasmids pIRESneo2 (Clontech R©, Paris, France) containingOATP1B1
or OATP1B3 were available in the lab and were prepared by the group of Prof.
Hagenbuch [61]. The cDNA of OATP1B1 or OATP1B3 was cloned from pIRES-
neo2 into the pcDNA3.1+ by sequential digestion using NotI first and subse-
quent NheI. The schematic of both vectors is shown in Fig. 3. Restricted DNA
was separated by gel electrophoresis and subsequently gel purified using the
QIAquick Gel Extraction Kit (Qiagen R©, Limburg, Netherlands). Afterwards
DNA was ligated and transformed into E.coli TOP10. Transformed E.coli were
plated on LB agar plates (35.6 g/L LB Agar EZMixTMin ddH2O, 50µg/ml car-
benicillin) and grown overnight at 37◦C. Several clones were picked and grown
overnight in LBmedium (20.6 g/L LB Broth EZMixTMPowder in ddH2O, 50µg/ml
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carbenicillin) shaking at 37◦C. DNA was then isolated with the GeneJET Plas-
mid Miniprep Kit (Thermo Fisher Scientific, Zurich, CH) and sent for sequenc-
ing to Microsynth R©(Zurich, CH) using their in-house standard primers (T7:
TAATACGACTCACTATAGG, BGH-rev: TAGAAGGCACAGTCGAGG).
Fig. 3: Vectors used for transfection.
Schematic of the vector pIRESneo2 (A) and pcDNA3.1+ (B)
To check for mutations the sequence of the inserted cDNAwas sequenced using
the primers given in Tab. 3. Primers were chosen to bind after every 600 bp’s.
The selected plasmids were linearized at the XhoI restriction site for one hour
at 37◦C using the FastDigest R©-system (Thermo Fisher Scientific, Zurich, CH).
Linearized DNAwas purified using the GeneJET PCR Purification Kit (Thermo
Fisher Scientific, Zurich, CH) and checked for proper linearization using agarose
gel electrophoresis.
2.2.3.3 Chemical transfection
FuGENE HD transfection agent (FuGENE) was used to transfect cells chem-
ically. In detail, L6 (2·105cells/well) and C2C12 (4·105cells/well) cells were
seeded in 6 well plates and incubated at 37◦C and 5%CO2 for 24 h. As rec-
ommended by the supplier different ratios of FuGENE and DNAwere applied.
The different ratios as well as the respective cell lines and plasmids (DNA) used
are listed in Tab. 4.
MATERIALS AND METHODS 21
Tab. 3: Primers used for complete insert sequencing after OATP1B3 or
OATP1B1 was cloned into the plasmid vector pcDNA3.1+,
respectively.
Tab. 4: Scheme of all transfection conditions used for chemical transfection.
The complexing process of DNA and FuGENEwas performed in FCS freemedi-
umOpti-Mem R©. For transfection, 150µl of complexing solution containing 3µg
DNA were added directly to every well without removing medium. Medium
was replaced by selection medium containing 1mg/ml G418 after 24 h and
changed every 3rdday for 8-10 days. When 6-well plates where confluent again,
cells were harvested by trypsinization and resuspended in selection medium
containing 0.5mg/ml G418. One 96-well plate containing 0.5 cells/well was
prepared from every transfection condition for limiting dilution cloning. The
residual cell suspension was transferred to two 35mm dish for RNA extraction
and to one 10 cm dish for freezing the cells.
2.2.3.4 Physical transfection
Electroporation was used to physically transfect L6 and C2C12 cells, based on
the protocol of Noya et al. [82]. In detail, cells were harvested from a confluent
10 cm dish, washed twice in PBS (phosphate buffered saline) and resuspended
in 3.5ml PBS. 0.8ml of the cell suspension was transferred to a 0.4 cm electro-
poration cuvette. After adding 50µl of DNA (OATP1B1 linearized plasmid:
232.86 ng/µl, OATP1B3 linearized plasmid: 588.80 ng/µl) cells were incubated
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for 10min on ice. Electroporation was conducted using the GenePulser R©(Bio-
Rad) instrument with the following settings:
• Capacitor: 960µF,
• Voltage: 0.22KV,
• Resistor: 100Ohms.
After electroporation cells were transferred back to a 10 cm dish containing
fresh L6/C2C12 culture medium without Pen/Strep. Medium was replaced
by selection medium containing 1mg/ml G418 after 24 h and changed every
3rdday for 12 days.
2.2.3.5 Limiting dilution cloning
To obtain a monoclonal cell population from a polyclonal mass of cells after
transfection a limiting dilution assay was performed. In detail, cells were har-
vested after they recovered from transfection by trypsinization and subsequently
mixed with fresh selection medium (0.5mg/ml G418). Cell density was deter-
mined using the automated cell counter Countess R©(Life Technologies, Carls-
bad, CA, USA) and thereafter diluted to a density of 5 cells/ml with selection
medium. 100µl of this solution was pipetted into every well of a 96-well plate
to reach a concentration of 0.5 cells/well. The plates were incubated at 37◦C
and 5%CO2. All 96-well plates were observed on a daily basis and medium
was exchanged every 3-4 days upon colony formation. Cells of confluent wells
were transferred to 6-well plates and later to 10 cm-dishes to increase the cell
population. Wells containing more than one colony were dropped out.
2.2.4 qRT-PCR using TaqMan R©-based gene expression analy-
sis
Cells to be analyzed were seeded on 35mm dishes and incubated at 37◦C and
5%CO2 until confluency. After aspiration of medium, 500µl of Trizol
R©were
added to every dish and cells were homogenized by pipetting up and down ten
times and flushing the surface of the culture dish. Cell homogenate was trans-
ferred to an Eppendorf R©-Tube and stored at –20◦C until further processing. Af-
ter thawing, RNAwas isolated following the “RNA Isolation Procedure” given in
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the Trizol R©reagent manual without adding glycogen [83]. RNA was eluted in
30-50µl RNase free water and concentration was measured using spectropho-
tometer NanoDrop ND-1000 (Thermo Fischer Scientific, Zurich, CH). For re-
verse transcription the High Capacity cDNA Reverse Transcription Kit (Life Tech-
nologiesTM , Carlsbad, CA, USA) was used. 10µl of sample containing 1µg of
RNAweremixedwith 10µl of RT-Mastermix (2.0µl, 10xRTBuffer, 0.8µl 25x dNTP,
2.0µl RandomPrimers, 1.0µl RTMultiscribe R©Reverse Transcriptase, 1.0µl RNases
inhibitor, 3.2µl RNase free water) and incubated for 60-90min at 37◦C. To stop
the reverse transcription samples were heated up to 85◦C for 5min and after-
wards cooled on ice. The obtained cDNA was diluted with 40µl RNase free
water. To perform qRT-PCR, 2µl of the diluted cDNA was mixed with 8µl
TaqMan-Master mix (5.0µl 2x TaqMan R©Fast Universal PCR Master Mix, 0.5µl
20x Primer, 2.5µl RNase free H2O) in a 348-well plate in triplicates.
2.2.5 Preparation of total membrane fraction
Cells were grown in 10 cm dishes till confluency at the day of the preparation
and treated with or without 5mM sodium butyrate (NaB) 24 h prior the prepa-
ration [84]. Dishes were rinsed three times with PBS and once with 0.25mM
sucrose. After adding 1ml of harvest solution (5mM sucrose, 2mM PMSF,
1mg/ml antipain-leupeptin) cells were scraped off using a cell scraper. To pre-
vent protein degradation all subsequent steps were performed on ice. Scraped
cells were frozen at −80◦C overnight and thawed in an ultrasonic bath for
2min. The cell suspension was homogenized using a 1ml syringe and 30G nee-
dle. The homogenate was centrifuged for 10min at 4◦C and 800g. To pellet the
membrane fraction, the supernatant was centrifuged for 1h at 100,000g. After
decanting the supernatant the pellet was resuspended in 150µl resuspension
buffer (250mM sucrose, 2mM PMSF, 1mg/ml Antipain-Leupeptin). Protein
concentration was determined using the BCA assay.
2.2.6 Western blotting
Western blotting was used to test the expression of OATP1B1- or OAPT1B3-
protein in transfected L6 and C2C12. Membrane fractions or whole cell lysates
were used as starting material. Whole cell lysate was prepared from a confluent
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10 cm dish, which was treated in the presence or absence of (NaB) 24 h before
lysing the cells. After aspirating the medium and washing with PBS twice,
1ml of RIPA-Buffer (150mM NaCl, 1% NP40, 0.5% w/v Sodium deoxycholate,
1mM EDTA, 0.1% SDS, 10% Glycerol, 50mM Tris-HCl pH8.0) was added to
dissolve the cells. Cell suspension was homogenized using a 26G-needle and
a 30G-needle consecutively. Protein concentration was determined using the
BCA assay. Proteins of whole cell homogenates or membrane fractions where
separated by SDS-PAGE on a 7.5% bis-acrylamide gel over night at 6mA per
gel using the “PROTEAN II xiCell” (BioRad). Separated proteins were trans-
ferred to a nitrocellulose membrane for 4 h in transfer buffer (192mM Glycine,
25mM TRIS, 0.1% w/v SDS, 20% v/v Methanol) using a voltage of 500V. Af-
ter the transfer, membranes were blocked for 30min in blocking solution (5%
milk powder in TBS-T). TBS-T consists of 150mM NaCl, 10mM Tris base, 0.1%
w/v Tween-20, pH7.6 with HCL. Primary antibody was added directly to the
blocking solution and thereby diluted depending on the antibody used. The
incubation lasts for 2-4 h at room temperature (RT) or overnight at 4◦C. After
washing three times with TBS-T the secondary antibody (goat anti-rabbit IgG
HRP-conjugate diluted 1:30,000 or a goat anti-mouse IgG HRP-conjugate di-
luted 1:3,000) were applied in blocking solution for 1h at RT. Blots were washed
three times with TBS-T and subsequently incubated with UptiLightTMHRP blot
substrate (Interchim, Montluçon, FRANCE) for 1min at RT. Membranes were
exposed to light sensitive films (Fuji Medical X-Ray Film) for 30 sec, 1min or
10min in a light-tight cassette. Exposed films were developed using a medical
film processor (Fujifilm, FPM 800a).
2.2.7 Transport assay using radiolabeled or fluorescent substrates
The transport assay with radio-labeled substrates in CHO, L6 and C2C12 cells
was typically performed in 35mm dishes in triplicates or quadruplicates [80].
Cells were grown to confluency at the day of the assay and treated with or
without NaB (5mM) 24 h prior to the assay [84]. Individual dishes were rinsed
three times with 2ml prewarmed sodium buffer and the uptake was started
by adding 1ml of uptake solution which was composed of prewarmed sodium
buffer and 0.3µCi/ml radiolabeled substrate supplementedwith unlabeled sub-
strate to adjust the required concentration. The sodium buffer (Earle’s bal-
anced salt solution) [85] consists of 5.3mMKCl, 1mMNaH2PO4 ·H2O, 0.8mM
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MgSO4·7H2O, 5.5mM D-Glucose, 20mM HEPES, 116.4mM NaCl, pH7.4 with
Tris base. For the fluorescence uptake assay, uptake solution was composed
of prewarmed sodium buffer and 5-20mM fluorescein. Dishes were incubated
at 37◦C for the given time on a heating plate or were kept in the cell incuba-
tor if the incubation time was longer than 5min. The uptake was stopped by
aspiration of uptake solution and rinsing the cells four times with 2ml of ice
cold sodium buffer (4◦C). To determine unspecific binding of the substrate to
the cells the zero time point was determined by adding 1ml ice cold uptake
solution after washing, followed by immediate aspiration and washing four
times with 2ml ice cold sodium buffer. The cells were then solubilized with
1ml 1%TritonX-100 (w/v) for at least 1h at RT and gently shaking. For liquid
scintillation counting 500µl of the lysate were used, while the rest was saved
for determining the protein concentration using the BCA assay. Net uptake val-
ues were obtained by subtracting uptake at 4◦C from total uptake at 37◦C. The
transport specific uptake was calculated as the difference in the uptake rate of
the transfected and wild-type cells.
2.2.8 BCA assay
To determine the protein concentration, 25µl of cell lysate were transferred into
a well of a 96-well plate and diluted with 25µl of distilled water. 25µl of bovine
serum albumin standard at different concentrations was diluted with 25µl of
sample solvent. After adding BCA-solution, the plate was incubated at 37◦C
for 30min. Subsequently light absorption was measured at 550nm using the
microplate reader “Ultramark (Bio-Rad, Hercules, CA, USA). The assay was
performed in duplicates.
2.2.9 Cell viability assay
To assess the toxic potential of different statins on muscle and non-muscle cells,
a cell viability assay using alamarBlue R©was conducted. In this assay active me-
tabolizing cells are converting resazurin, a non-fluorescent indicator dye, into
highly red fluorescent resorufin via reduction reactions. Five different statins,
atorvastatin, cerivastatin, pravastatin, rosuvastatin and simvastatin were tested
at different concentrations. Therefore, cells were seeded in 48-well plates and
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incubated for 24 h at 37◦C and 5%CO2. Statins were dissolved in DMSO and
were added at different concentrations directly into the medium covering the
cells. In case an inhibitor study was performed, indocyanine green ICG (10µM)
or E3S (300µM) were added one hour before statin treatment. After 24 h, 48 h
or 72 h alamarBlue R©solution was added (10% percent of total volume) to ev-
ery well and incubated for 4 h to 6 h at 37◦C and 5%CO2. Fluorescence was
measured using the plate reader “Twinkle LB970 (Berthold Technologies, Bad
Wildbad, Germany) with excitation wavelength at 560 nm and emission wave-
length at 590 nm. IC50-values were calculated using a four parameter logistic
nonlinear regression model.
2.2.10 Confocal laser scanning microscopy (CLSM)
Cells were seeded on sterile cover slips in 6-well plates at a density of 100,000
cells/well and incubated at 37◦C and 5%CO2 until confluency and treated with
or without NaB (5mM) 24 h prior the cells were confluent. Medium was re-
placedwith fixation solution containing 4% (w/v) paraformaldehyde and 0.5%,
0.75%, or 1% (w/v) TritonX-100 in phosphate buffer. Phosphate buffer was pre-
pared by mixing 200mM Na2HPO4 and 200mM NaH2PO4 until pH7.4 was
reached. Cells were fixed for 1h at RT. Fixation solutionwas aspirated and cover
slips were washed three times with PBS. Afterwards cover slips were incubated
consecutively with 0.25% (w/v) NH4Cl in PBS for 5min, 0.1% (w/v) saponin in
PBS for 10min , 0.1% (w/v) saponin and 2 % (w/v) gelatin in PBS for 30min,
0.1 % (w/v) saponin in PBS for 10min twice, and finally 0.1% saponin (w/v)
and 1% (w/v) BSA in PBS for 10min. Cover slips were transferred to a humid
chamber lined with parafilm, and 150µl of primary antibody was added drop-
wise at different concentrations. The incubation lasts for 2h at RT or overnight
at 4◦C. Cover slips were washed three times with 0.1% saponin (w/v) and 1%
(w/v) BSA in PBS. The secondary antibody Alexa Fluor R©488 goat anti-rabbit
IgG was applied at different concentrations for 1h at RT in a humid chamber
in the dark. Primary and secondary antibodies were diluted in 0.1% Saponin
(w/v) and 1% (w/v) BSA in PBS.
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2.2.11 Apoptosis assessed by measuring caspase-3 activity
To measure caspase-3 activity, a caspase-3-specific substrate coupled to a fluo-
rophore was used, in this case Ac-DEVD-AMC (Asp-Glu-Val-Asp 7-amido-4--
methylcoumarin). This substrate consists of a peptide sequence [Asp-Glu-Val-
Asp (DEVD)] which is specifically recognized by caspase-3. DEVD is coupled
to the fluorophore 7-amido-4-methylcoumarin (AMC) and is cleaved of by hy-
drolysis of caspase-3 upon binding. The released AMC is directly proportional
the amount of active caspase-3 [86, 87]. To assess caspase-3 activity, cells were
seeded at a density of 10,000 cells per well into white 96-well microplate with
Clear Bottom (ViewPlate-96, PerkinElmer R©). Plates were incubated for 48 h at
37◦C, 5%CO2 in humidified incubator. Medium was removed by inverting the
plates and replaced with medium containing statins at the given concentra-
tions. Cells were incubated up to 6 h at 37◦C, 5%CO2 in humidified incubator.
Medium was removed by shaking of and cells were washed twice with PBS.
Afterwards, cells were lysed in 60µl ice cold lysis buffer (120mM NaCl, 5mM
EDTA, 0.5%NP-40 and 25mM Tris-HCl, pH8) diluted 1:2 in PBS and incubated
for 10min at 37◦C. Lysed cells were homogenized by pipetting 15 times up and
down. An aliquot of 10µl was transferred to a new 96-well plate for protein
determination. Lysed cells were mixed with 50µl of 12.5µM Ac-DEVD-AMC
(dissolved in PBS) and incubated for 1h at 37◦C. Fluorescent signal was read
at excitation of 365 nm and emission of 410-460 nm using GloMax R©-Multi + Mi-
croplate Multimode Reader with Instinct R©software (Promega R©, Zurich, CH).

3 RESULTS
3.1 Statin toxicity in non-muscle cell lines
To investigate the toxic potential of statins in non-muscle cells, the fibroblast cell
line CHO expressing different OATPs was used. These cell lines were formerly
transfected to express OATP1B1, or 1B3, or 2B1 [61, 80]. To asses statin toxicity,
cells were treated with increasing concentrations of the lipophilic cerivastatin,
simvastatin, or atorvastatin and the hydrophilic pravastatin or rosuvastatin for
72 h. Cell viability was measured using alamarBlue R©. The results presented in
Fig. 4 indicate that lipophilic statins are more toxic (lower IC50) compared to
hydrophilic statins, with cerivastatin showing the strongest toxic effect (lowest
IC50), while pravastatin appeared to be the least toxic statin. For the latter, cells
start to die first in the mM-range (Fig. 4). IC50 values between the different cell
lines did not differ significantly for all the statins tested (Tab. 5).
Tab. 5: IC50 values of cell viability assay. Cells were treated with the indicated
statins for 72h. IC50 values were calculated using a four parameter
logistic nonlinear regression model.
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Fig. 4: Analysis of cell viability assay after statin treatment.
CHO cells Expressing OATP1B1, or -1B3, or -2B1 and control cells (wt)
were treated with increasing concentrations of the indicated statin over
72h and viability was determined as described in materials and
methods. Each data point represents the mean ± S.D. (standard
deviation) of three replicates.
3.2 Statin toxicity in non-muscle cell lines compared
to muscle cells
To investigate whether muscle cells (L6 and C2C12) show a distinct pattern of
susceptibility after statin treatment compared to the fibroblast cell line CHO,
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cells were incubated for 72 hwith increasing concentrations of lipophilic cerivas-
tatin und hydrophilic pravastatin. Cell viability was then determined with
alamarBlue R©. Results indicate that muscle cells are indeed more susceptible
to statins when compared with the non-muscle cell line CHO. Interestingly,
pravastatin shows toxicity in L6 cells already at lowµM-concentrations, which
is not the case for C2C12, where pravastatin appeared to be toxic at concentra-
tions higher than 100µM (Fig. 5).
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Fig. 5: Analysis of cell viability assay after 72h statin treatment.
L6, C2C12 and CHO-cells were treated with increasing concentrations
of cerivastatin (left) or pravastatin (right) over 72h. Each data point
represents the mean ± S.D. of three replicates.
IC50 values indicate that muscle cells are more sensitive against the lipophilic
cerivastatin compared to the non-muscle fibroblast cell line CHO (Tab. 6). Com-
paring themuscle cells, C2C12 cells were less susceptible than L6 against cerivas-
tatin. For pravastatin it was not possible to calculate IC50 values from the data
points obtained. However, this experiment demonstrated that muscle cells are
more sensitive towards cerivastatin and pravastatin than CHO cells.
Tab. 6: Log IC50 values and 95% confidence intervals of the log IC50 values.
Cells were incubated for 72h with cerivastatin.
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3.3 Transfection of L6 and C2C12 cells
3.3.1 Killing curve
To determine the concentration of G-418 required for killing all L6 and C2C12
wt cells, a cell survival assay was performed. Therefore, cells were treated with
increasing concentrations of G-418. After eleven days cell viability was mea-
sured using the alamarBlue R©assay. The lowest concentration of G-418 killing
100% of the wild type cells was chosen to treat cells after transfection. The
killing curve is shown in Fig. 6. IC50 of G-418 was 403µg/ml and 557µg/ml for
L6 and C2C12 cells, respectively. After transfection, 1mg/ml of G-418 was used
to select successfully transfected cells, as this concentration was the lowest to
kill all cells after eleven days of G-418 treatment.
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Fig. 6: Killing curve
C2C12 and L6 cells treated with increasing concentrations of G-418
(Geneticin) for 11 days to establish a killing curve. Each data point
represents the mean ± S.D. of three replicates.
3.3.2 Transfection with OATP1B1 and OATP1B3 in pIRESneo2
vector
Plasmids of OATP1B1 and -1B3 in pIRESneo2 vector were already available
in the lab [61]. After sequencing, plasmids were amplified and purified for
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transfection. To enhance the chance of proper insertion into genomic DNA of
the target cells, plasmids were linearized by restriction digestion. Samples of
the plasmids were separated with an agarose gel to check proper linearization.
Fig. 7 shows samples of the linearized plasmids (lane 1 & 3) and the undigested
controls (lane 2 & 4)
Fig. 7: Linearization of plasmids
M: DNAMarker VII (Roche, Basel, CH), 1: OATP1B1 linearized, 2:
OATP1B1 undigested, 3: OATP1B3 linearized, 4: OATP1B3 undigested
For transfecting cells, a chemicalmethod using FuGENE and a physical method,
electroporation, were used. For the latter different settings of voltage and ca-
pacitance were tried, but none of the tested settings resulted in surviving cells.
As both transfection methods where done in parallel and chemical transfec-
tion resulted in surviving cells, electroporation method was not further op-
timized. For transfecting cells with FuGENE different ratios of FuGENE to
DNA were used, as this ratio can have an influence on the efficacy of trans-
fection [88]. This FuGENE to DNA ratio is always part of the name of the
respective clone. After 24 h, transfected cells were put under selection pres-
sure by adding G-418 (1mg/ml) to the culture medium. As soon as cells re-
covered and reached 80-90% confluency, a limiting dilution cloning assay was
performed to obtain a monoclonal cell population starting from a polyclonal
mass of cells. Pools of cells, which recovered from transfection are indicated
below (Tab. 7, shaded in blue). The limiting dilution cloning assay resulted in
120 clones which were subsequently tested for their capacity to transport pro-
totypical OATP substrates.
Previous experience in the laboratory had shown that directly screening for
functional active clones can successfully speed-up the process of finding a proper
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Tab. 7: Conditions used for limited dilution cloning assay are shaded in blue.
clone [61]. Therefore, clones were directly screened for functional transport us-
ing a cellular uptake assay with tritium labeled E3S, which is a known sub-
strate of OATP1B1 and OATP1B3 [89]. For screening, cells were grown on 3 cm
culture dishes incubated for 5min with uptake solution at 37◦C. To calculate
nonspecific binding of substrate to the plasma membrane, another set of cells
was flushed with ice-cold uptake solution representing the zero value (0min,
4◦C). Net uptake values were obtained by subtracting uptake at 4◦C from total
uptake at 37◦C. The number of clones tested is listed in Tab. 8.
Tab. 8: Amount of clones tested for transport with the OATP1B1 and -1B3
substrate estrone-3-sulfate.
Of the transfected L6 cells, none of the tested clones showed a difference of
two-fold transport rate compared to the wild type cells. This threshold should
allow selecting clones, which express an amount of transport protein amenable
to detection by protein methods like e.g. Western blotting. Result of screening
for some of the tested clones is shown in Fig. 8. Therefore, transfection was
repeated with the same conditions as listed in Tab. 7. The results of the second
transfection of L6 cells is described later.
In contrast, after transfecting the C2C12 cell line, about 6 clones per gene dis-
played specific uptake of E3S. The clones with the highest transport rates were
then tested again together in the same uptake experiment. Therefore, the cells
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Fig. 8: Cellular uptake of 3H-estrone-3-sulfate (5µM) after 5min.
L6 clones transfected with OATP1B1 or -1B3 cDNA where tested for
uptake of estrone-3-sulfate after single cell cloning. Data show net
uptake values calculated by subtraction of zero value from 5min time
point. Each bar represents the mean ± S.D. of three replicates.
were incubated for 5min with uptake solution containing E3S (5µM) as sub-
strate (Fig. 9). From this experiment, it was decided to focus on clones express-
ing OATP1B1, as clones expressing OATP1B3 did not reproducibly show an at
least twofold transport rate compared to the wild type. To further narrow down
the amount of clones, three clones expressing OATP1B1 were tested, namely
C2C12 OATP1B1 clone 1, 6, and 7 (all 9:2), at one and 5min (Fig. 10). Clone 1
was included here, because it showed transport in an earlier experiment (data
not shown).
After this experiment, the work was proceeded with C2C12 OATP1B1, 9:2,
Clone 6 hereinafter called C2C12 1B1. To characterize this clone, a time course
experiment was conducted to follow the transport over time (Fig. 11). Cells
were incubated for 30 s, 1min, 2min, and 5min with E3S (5µM). Fig. 11 shows
that uptake of the standard OATP1B1 substrate E3S is steadily increased up to
5min and largely exceeded the uptake into the non-transfected parent cell line.
Myoblasts are precursor cells of the final muscle tissue in vivo. They need to
fuse for building multi-nucleated muscle cells, which are subsequently able to
mature into various classes of myofibers [90]. To differentiate myoblasts in vitro
into long and multinuclear myotubes, they are cultured under a low level of
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Fig. 9: Cellular uptake of 3H-estrone-3-sulfate (5µM) after 5min.
Clones transfected with OATP1B1 or OATP1B3 cDNA where tested for
uptake of estrone-3-sulfate. Data show net uptake values calculated by
subtraction of zero value from 5min time point. Each bar represents
the mean ± S.D. of three replicates.
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Fig. 10: Cellular uptake of 3H-estrone-3-sulfate (5µM) in C2C12 cells.
C2C12 wild type cells (wt) and three clones expressing OATP1B1
(1B1) were tested for estrone-3-sulfate at 1min and 5min. Data show
net uptake values calculated by subtraction of zero value. Each data
point represents the mean ± S.D. of three replicates.
growth factors. Instead of using 10% FCS like in normal subcultivation, the
medium contained 2% horse serum [76]. As C2C12 myotubes are closer to the
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Fig. 11: Transport of 3H-E3S (5µM) over time.
Transport into C2C12 OATP1B1 (red) and C2C12 wild type (green)
cells. Data show net uptake values calculated by subtraction of zero
value. Each data point represents the mean ± S.D. of three replicates.
in vivomyofibers than myoblasts are, they may provide a better model of the in
vivo situations. Therefore, it was tried to differentiate cells of the clone into my-
otubes by treating C2C12 wt and C2C12 1B1 cells with differentiation medium
for 5-10 days. The wild type cells already formedmyotubes after 3-4 days while
the selected clone did not, even after eleven days (Fig. 12). In contrast, cells of
this clone are still able to fuse, shown in Fig. 13, but they do not form long
myotubes in large numbers as the wild type cells do. Instead, the rarly form
roundish, huge cells harboring several cell nuclei. Therefore, all subsequent
investigations were performed with myoblasts.
3.4 Uptake of statins
After having identified a clone showing proper transport of the OATP1B1model
substrate E3S, uptake of different statins by this clone was tested and compared
to the OATP-transfected CHO cells. Cells were incubated with radioactively
labeled pravastatin, simvastatin, cerivastatin or E3S at 5µM for 3min, whereby
the latter substrate served as assay control. CHO OATP1B1 transfected served
as positive control. The results (Fig. 14) demonstrate that E3S and pravastatin
are taken up into the CHO OATP1B1 cells proving the success of this assay.
C2C12 1B1 cells are also taking up E3S and pravastatin, proving that these
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Fig. 12: Differentiation of muscle cells.
C2C12 wild type cell (left) and C2C12 OATP1B1 (right) cells were
treated with differentiation medium for 11 days to form
multi-nucleated myotubes.
Fig. 13: Differentiated C2C12 OATP1B1 cells.
Cells were treated for 10 days with differentiation medium. Cells of
this clone are still able to fuse, shown by multi nucleated cells (red
arrow), but do not form long myotubes in large amounts.
cells express a functional statin transporter. Interestingly, the uptake values
for cerivastatin and for simvastatin are at least one order and two orders of
magnitude higher, respectively, when compared to E3S. For simvastatin there
is no difference in uptake when comparing transfected and parent cell line, ap-
plicable for CHO cells as well as for C2C12 cells. A slightly higher uptake of
cerivastatin was observable for CHO OATP1B1 cells compared to the nontrans-
fected control. This effect is not apparent in C2C12 cells. With this test it was
possible to demonstrate that C2C12 1B1 cells express a functionally active statin
transporter.
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Fig. 14: Analysis of uptake assay with different statins as substrate.
CHO and C2C12 cells were incubated for 3min with 5µM of E3S,
pravastatin, simvastatin or cerivastatin. Data show net uptake values
calculated by subtraction of zero value. Each data point represents the
mean ± S.D. of three replicates.
It is well established that transport activity of OATPs/Oatps is stimulated by
an acidic extracellular environment ([64, 65]. Nozawa et al. demonstrated that
HEK cells expressingOATP2B1 transport pravastatin to a greater extent at pH5.0
compared to pH7.4 [64]. Muscle cells exhibit a lower pH compared to other tis-
sues or blood. Carter et al. showed that intracellular pH in rat skeletal muscle
cells is about 6.0, but the evidence for this is controversial [91]. To test the hy-
pothesis whether statins show higher uptake under low extracellular pH con-
ditions, transport experiments with different statins were performed at slightly
acidic conditions (pH6.5) and under physiological conditions (pH7.4). There-
fore, C2C12 wt cells and C2C12 1B1 cells were incubated with uptake solution
(pH6.5 or pH7.4) including 5µM of E3S, pravastatin, simvastatin, or cerivas-
tatin for 3min. The results in Fig. 15 show that uptake of E3S at pH6.5 was de-
creased in C2C12 1B1 compared to pH7.4. Still, the transfected cell line showed
higher uptake compared to the control cells. Pravastatin uptake was increased
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in C2C12 1B1 and control cells. Here, no difference was observed in the up-
take by transfected and wild type cells. For simvastatin, the pH seems to have
no influence at all, as uptake values at pH6.5 are similar to those at pH7.4.
Additionally, similar differences were observed in uptake between C2C12 1B1
and control cells at pH6.5 & pH7.4 respectively. For cerivastatin, uptake was
approximately twofold higer at pH6.5 for transfected and control cells, with
C2C12 1B1 showing higher uptake than the wild type cells, which was not the
same as at pH7.4.
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Fig. 15: Comparison of statin transport at pH6.5 and pH7.4.
C2C12 1B1 and control cells were incubated for 3min with 5µM of
E3S, pravastatin, simvastatin or cerivastatin. Data show net uptake
values calculated by subtraction of zero value. Each data point
represents the mean ± S.D. of three replicates.
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3.5 Statin toxicity
To investigate the toxicity of statins against mouse skeletal muscle cells and to
study the effect of the statin transporter OATP1B1 on toxicity, C2C12 wt cells
and C2C12 1B1 cells were treated with different statins over a broad range of
concentrations for 48 h. The cell viabilitywas then assessedwith the alamarBlue R©assay.
The results of this test indicate that the toxicity of statins is different depending
on their lipophilicity. While lipophilic statins like cerivastatin or simvastatin
are more potent to induce cell death, the hydrophilic pravastatin was not toxic
up to 1mM when cells were treated for 48 h (Fig. 16). IC50 values between the
different cell lines did not differ significantly for all the statins tested (data not
shown).
3.5.1 Impact of OATP inhibition on statin toxicity
In high concentrations ES3 acts as competitive inhibitor towards another OATP
substrate, when both are applied in parallel. As the previous toxicity test showed
no difference in toxicity when comparing wild type and transfected cells af-
ter statin treatment, the toxicity experiments were repeated in the presence of
the OATP1B1 substrate E3S. This allows testing, whether inhibition of OATPs
changes the susceptibility of transfected cells towards statins. For this exper-
iment, cells were pretreated with 300µM of E3S one hour before statins were
added [52]. E3S alone had no effect on the morphology and viability of C2C12
wt and transfected cells (data not shown). After 72 h, cell viability was as-
sessed using the alamarBlue R©assay. In this assay only cerivastatin and sim-
vastatin were tested, as previous studies showed that these two are the most
toxic statins, judged by their IC50 values. Results in Fig. 17 show cell viability
in percentage of control (DMSO). IC50 values and 95% confidence intervals are
shown in Tab. 9 and were calculated using a four parameter logistic nonlinear
regression model.
As shown in Fig. 17, E3S pretreatment exhibited approximately twofold higher
IC50 values in C2C12 wt and C2C12 1B1 cells treated with cerivastatin (0.56µM
and 0.68µM) compared to E3S untreated cells (0.27µM and 0.27µM) (Tab. 9),
supporting the concept of a transportdependent statin uptake. Interestingly,
E3S also had an effect on the wt cells, which is discussed later. The trend for
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Fig. 16: Analysis of cell viability assays after statin treatment.
C2C12 wild type (wt) and OATP1B1 (1B1) cells were treated for 48h
with different statins. Cell viability was measured with
alamarBlue R©assay. Cells were exposed to increasing
concentrations of statins for 48 h. Each data point represents the
mean ± S.D. of three replicates.
higher IC50 values with E3S pretreatment was also observed for simvastatin
but the effect was not as prominent as with cerivastatin. Here, IC50 values are
also higher when cells are pretreated with E3S, but 95% confidence intervals are
overlapping (Tab. 9).
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Fig. 17: Cell viability after statin treatment with or without pretreatment of
competitive inhibitor E3S.
Cells were treated with cerivastatin (left) or simvastatin (right).
Pretreatment was conducted 1h before statins were added with
300µM E3S (+E3S) or DMSO (w/o E3S). Each data point represents
the mean ± S.D. of three replicates.
Tab. 9: IC50 values and 95% confidence intervals of cell viability assay. Cells
were treated with (+E3S) or without (w/o E3S) E3S (300 µM) prior
statin treatment.
3.6 Investigations to study the expression ofOATP1B1
in transfected C2C12 cells
After having identified a functional active clone of C2C12 cells transfected with
OATP1B1, investigatoins were performed to study the expression and the local-
ization of OATP1B1 at the protein and RNA level.
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3.6.1 Subcellular localization of OATP1B1 in C2C12 cells
To test subcellular localization of the OATP1B1 protein in the cell membrane
of C2C12 cells, immunocytochemistry experiments were conducted. CHO cells
transfected with OATP1B1 were used as control, as these cells are well known
to express OATP1B1 [61]. After cells were confluent they were treated with
a fixation solution containing Triton X-100. Best results were obtained with
0.75% Triton X-100 (data not shown). The primary antibody used, was a rabbit
anti-OATP1B1-antibody [57]. The results of immunocytochemistry are shown
in Fig. 18 and demonstrate that OATP1B1 is expressed in the cell membrane
of CHO OATP1B1 cells. To get a proper signal from the transfected cell line,
the laser power was increased by about a factor of three. C2C12 wt cells were
then recorded with the same settings. The transfected cell line did not show
the expected expression of OATP1B1 in the cell membrane, instead the signal
appeared all over the cell. However, it seemed that the signal in the transfected
cells was slightly stronger compared to control cells indicating that transfection
was successful, but the protein is not integrated in the plasma membrane.
3.6.2 Western blot analysis of C2C12 1B1 cells
As immunocytochemistry failed to demonstrate the proper expression of OATP1B1,
Western blot analysis was used to test for OATP1B1expression. Therefore, cells
were lysed with RIPA-buffer; proteins were separated by gel electrophoresis
and transferred to nitrocellulose membrane. The primary antibody was a rabbit
anti-OATP1B1-antibody produced previously in this laboratory [57]. Although
the method was optimized and several parameters like antibody concentra-
tion, incubation time and temperature where modified, results were not repro-
ducibly conclusive. The inhouse antibody was raised against the C-terminus
[57]. In addition, different commercially available antibodieswere tested, which
were raised against the middle region (A) and against the N-terminus (B). The
antibodies tested were:
A - SLCO1B1 antibody (middle region) from Aviva Systems Biology
(ARP43914_P050),
B - Mouse monoclonal antibody against SLCO1B1 from Creative Diagnos-
tics (CABT-36050MH).
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Fig. 18: Analysis of confocal laser scanning microscopy.
Cells were stained with anti-OATP1B1-antibody, followed by Alexa
Fluor R©488 anti-rabbit IgG secondary antibody (red) plus DAPI
staining for nuclei (green). Laser power was increased by about
a factor of three for C2C12 cells.
All Western blots performed with the commercial antibodies failed to show
OATP1B1 in CHO cells expressing OATP1B1 (data not shown). Therefore, these
antibodies were not used for further investigations.
3.6.3 qRT-PCR using TaqMan R© based gene expression analysis
to detect OATP1B1 RNA
To analyze the expression of OATP1B1 at the RNA level, a quantitative real
time PCR was performed with RNA extracts from C2C12 1B1, CHO OATP1B1
and the corresponding control cells. Data were normalized to mouse beta-actin
RNA. Expression level of wild type cells were used as calibrator and set to
one, although they do not express OATP1B1. CHO OATP1B1 cells show about
one thousand fold change of OATP1B1 mRNA compared to the wt cells, while
C2C12 1B1 cells do not show any difference in OATP1B1 expression compared
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to thewild type cells (Fig. 19). It was not possible to detect the RNA of OATP1B1
in the clone, which was selected previously by its transport results shown in
Fig. 11. The experiment was repeated several times but OATP1B1 expression
was not observed in the clone.
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Fig. 19: Relative mRNA expression of OATP1B1
Bars indicate fold change of OATP1B1 mRNA expression normalized
to the corresponding wild type cell line. Each data point represents
the mean ± S.D. of three replicates.
3.7 Rat L6 cells transfected with OATP1B1 or -1B3
As the results with C2C12 cells were inconclusive, investigations were then fo-
cused on the L6 cell line which was already transfected. The limiting dilution
cloning to obtain single clones was already conducted in parallel to the C2C12
investigations. Here, about 50 clones per gene were obtained. In the first step,
RNA of 25 clones of each gene of interest was isolated and a qRT-PCR was per-
formed to check the RNA expression level of OATP1B1 or -1B3. To simplify the
analysis, the results shown in Fig. 20 are presented as fold change of wild type
cells. Data were normalized to rat beta-actin. The qRT-PCR reveals that RNA
of OATP1B1 or- 1B3 is expressed in several clones of L6 cells. Clones showing
a high expression level of the respective gene were selected to for further anal-
ysis. The expression of the OATP1B1 rat orthologue Slco1b2 was additionally
tested in this assay. Both sequences exhibit a 75% identity at mRNA-level when
they were aligned using BLAST. The OATP2B1 rat orthologue Slco2b1 was also
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tested as this transporter has been shown previously to transport statins as well
[92]. For both genes it was not possible to detect RNA in C2C12 wt cells.
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Fig. 20: Relative mRNA expression of OATP1B1 or -1B3 in L6 clones
The qRT-PCRs were performed with cDNA samples from isolated
mRNA of L6 clones transfected with OATP1B1 or -1B3 cDNA. Bars
indicate the fold change mRNA expression of OATP1B3 (left) and
OATP1B1 (right). Each data point represents the mean ± S.D. of three
replicates.
For further characterization the following clones were selected:
• L6 OATP1B1: Clone2, 8, 12, 14, 22, 23, 24,
• L6 OATP1B3: Clone2, 3, 6, 12, 19, 22.
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Western blots were performed to elucidate the expression of OAPT1B1 or -1B3
at the protein level. Therefore, cells were lysed at a confluency of about 90%
using RIPA-buffer containing protease inhibitors. Nitrocellulose membranes
were probed with rabbit anti-OATP1B1-antibody [57] or rabbit anti-OATP1B3-
antibody [81]. Fig. 21 shows the Western blot analyses of cell lysates of L6
clones expressing OATP1B1 and control cells. As OATP1B1 has previously been
shown to appear around 75 kDa [81], the band of interest is located between
75kDa and 100kDa as indicated by an arrow in Fig. 21. The positive control
CHO OATP1B1 (Fig. 21, lane 10) shows high expression of OATP1B1. In all
tested clones OATP1B1 is not expressed, as the band of interest also appears in
the wild type control.
Fig. 21: Western blot analysis of OATP1B1 expressed in different clones of
L6 cells
Cells were treated with (+) or without (-) sodium butyrate. M: Marker,
1: Clone 2, 2: Clone 8, 3: Clone 12, 4: Clone 14, 5: Clone 22; 6: Clone 23,
7: Clone 24, 8: L6wt, 9: CHOwt, 10: CHOOATP1B1
Western blot analyses of L6 clones expressing OATP1B3 and control cells are
shown in Fig. 22. OATP1B3 has 702 amino acids and was previously shown to
appear with a double band at 75 kDa and 105 kDa on Western blots [81]. The
positive control clearly shows expression of OATP1B3 (Fig. 22, lane 2). Com-
paring clones of L6 transfected with OATP1B3 (Fig. 22, lane 3-8) with wt cells
(Fig. 22,lane 9) reveals no difference in OATP1B3 expression suggesting that
OATP1B3 is not or only to minor extent expressed in the clones tested.
In parallel to these experiments, trials were run to show OATP1B1 or -1B3 pro-
tein with confocal laser scanning microscopy in the selected L6 clones. There-
fore, cells were seeded on sterile cover slips and grown until confluency. Cells
were fixed with fixing solution, where best results were obtained with 0.75%
Triton X-100. Fixed cells were probedwith affinity purified rabbit anti-OATP1B1-
antibody followed by goat anti-rabbit IgG Alexa Fluor R©488-conjugat antibody.
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Fig. 22: Western blot analysis of OATP1B3 expressed in different clones of
L6 cells
M: Marker, 1: CHOwt, 2: CHOOATP1B3, 3: L6 clone 2, 4: L6 clone 3,
5: L6 clone 6, 6: L6 clone 12, 7: L6 clone 19, 8: L6 clone 22, 9: L6wt, 10:
empty
Several attempts failed to show OATP1B1 expression in L6 clones although
CHO control cells showed strong expression of transport protein in the cell
membrane (Fig. 23). Same holds true for the selected L6 clones transfected with
OATP1B3 cDNA.
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Fig. 23: Analysis of confocal laser scanning microscopy
L6 clones transfected with OAPT1B1 cDNA and control cells. Samples
were probed with affinity purified rabbit anti-OATP1B1-antibody
followed by goat anti-rabbit IgG Alexa Fluor R©488-conjugat
antibody (red) and DAPI (blue) to stain nuclei. Laser power
was increased about factor two for L6 cells.
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3.8 New transfection of C2C12 and L6 cells
As it was not possible to demonstrate expression of either the OATP1B1 and
-1B3 RNA, it was reasoned the vector so far used may not be compatible with
C2C12 or L6 cells. Therefore, pcDNA3.1+ was used next. The new vector
pcDNA3.1+ was previously shown to work with C2C12 and L6 cells to stably
express the α1- and α2-subunit of AMP-activated protein kinase [93]. Addition-
ally, pcDNA3.1+ contains the BGHpA site, which is a signal for accurate and ef-
ficient polyadenylation [94], while pIRESneo2 contains only a synthetic intron
(IVS) known to enhance the stability of the mRNA [95]. It has been clearly es-
tablished that the poly(A) tail is essential for the stability, transport across the
nuclear membrane, and translation of most mRNAs [96, 97].
3.8.1 Recloning ofOATP1B1 andOATP1B3 cDNA frompIRES-
neo2 into pcDNA3.1+
After cloning of OATP1B1/ -1B3 cDNA into pcDNA3.1+ and transformation of
plasmids into competent E.coli, several clones were picked and DNA was iso-
lated. DNA of four clones of each cDNA was sent for sequencing using only
the flanking primers of the inserted gene (T7 and BGH-reverse) to check the
correct orientation. As all clones were positive, the integrity of these expression
vectors and the lack of mutations were confirmed by DNA sequencing of the
insert. Prior to transfection, plasmids were linearized using restriction enzyme
XhoI and subsequently separated with an agarose gel to check proper lineariza-
tion. Undigested plasmids appear at lower molecular weight as the circular
form tends to supercoil, and thus migrates faster through the gel (Fig. 24, lanes
1 and 4), while the linear form appears at highermolecular weight (Fig. 24, lanes
2 and 5).
3.8.2 Transfection of muscle cells using pcDNA3.1+ vector
For transfecting L6 and C2C12 with the new plasmids the same conditions were
used as already described (Tab.7). All different transfection conditions resulted
in surviving cell. Therefore, RNA was isolated from all these cells to check
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Fig. 24: Linearization of plasmids after cloning OATP1B1 and OATP1B3
into pcDNA3.1+
1: OATP1B3 undigested, 2: OATP1B3 linearized, 3: Marker, 4:
OATP1B1 undigested, 5: OATP1B1 linearized
the mRNA levels of OATP1B1 and -1B3 by qRT-PCR. All samples showed high
amount of the expected RNA (Fig. 25).
Subsequently a limiting dilution cloning of all transfection conditions was per-
formed to receive single cell clones. The clones obtained in this assay are listed
in Tab. 10. The strategy was changed this time to avoid problems encountered
in the previous rounds of characterization, where a functional active clone was
identified without reproducibly demonstrating the expression of OATP1B1 or-
1B3 at the protein or RNA level. During the limiting dilution cloning, before
freezing the single cell clones for the first time, all clones were tested for uptake
of sodium fluorescein (NaFluo) and in parallel cell lysates were prepared for
possible later RNA isolation. As NaFluo is a substrate of the OATPs [98], this
assay allowed to quickly decide whether a clone is suitable or not. Therefore,
clones were seeded in 6-well plates (single point measurement) and cultured
until 80-90% confluency. To measure uptake, cells were incubated with 5µM
NaFluo for 5min. Plates were then immediately observed under fluorescent
microscope. Clones showing no uptake at all were excluded from further inves-
tigations. The clones selected for further characterization are listed in Tab. 11.
Tab. 10: Amount of clones received by limiting dilution cloning.
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Fig. 25: qRT-PCR results of transfection conditions
The qRT-PCRs were run with cDNA samples from isolated mRNA of
transfection conditions. Bars indicate the ct-values of fluorescent
signal to cross the threshold. Gene of interest is indicated in red and
housekeeping gene in green. Each data point represents the mean ±
S.D. of three replicates.
Tab. 11: Clones selected after NaFluo uptake assay for further investigations.
3.8.3 qRT-PCR using TaqMan R© based gene expression analysis
to detect OATP1B1 and -1B3 RNA
Subsequently the RNA of the preselected clones was isolated from the samples
prepared during the limiting dilution cloning to check the expression level of
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OATP1B1 or -1B3 by qRT-PCR after reverse transcription. Results of qRT-PCR
revealed that several clones express OATP1B1 or -1B3 mRNA in C2C12 cells,
respectively (Fig. 26).
Fig. 26: qRT-PCR results of C2C12 clones expressing OATP1B1 or -1B3
The qRT-PCRs were run with cDNA samples from isolated mRNA of
C2C12 clones transfected with OATP1B1 or -1B3 cDNA. Bars indicate
the log fold change of mRNA expression of OATP1B1 (A) and
OATP1B3 (B). Each data point represents the mean ± S.D. of three
replicates.
3.8.4 Functional screening using the transport assay
Based on these results, clones showing the highest expression level were chosen
(Tab. 12) to be tested for uptake using [3H]-E3S to evaluate uptake rates quanti-
tatively.
Tab. 12: Clones selected after qRT-PCR for further investigation.
The uptake assay revealed that three clones of C2C12 OATP1B1 (7:2 Clone2,
7:2 Clone5, and 7:2 Clone14) showed proper transport (Fig. 27). For OATP1B3
none of the selected clones showed suitable transport values. The previously
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selected clone C2C12 1B1 was run as positive control and showed about five
times more uptake than C2C12 wt cells. For both uptake assays the control
cell lines CHO 1B1 and CHO 1B3 showed low uptake values. These values
are typical for uptakes assays where NaB treatment 24 h prior conducting the
assay is omitted. NaB was previously shown to boost protein expression in
CHO cells [84]. As the effect of NaB to C2C12 cell is unknown, the screening
was performed without NaB treatment. After finally selecting the best clone,
namely C2C12 OAPT1B1, 7:2 Clone2 (hereinafter called C2C12 1B1 Cl.2) the
question arose if NaB pre-treatment can enhance transport. To test whether
NaB is toxic at all, a cell viability assay was performed over a broad range of
concentrations up to 200mM. The results (Fig. 28A) revealed that NaB is toxic
but only in the high millimolar range. Cell viability of NaB treated cells starts
to decrease at 1mM. As CHO cells are routinely treated with 5mM in our lab
prior to the uptake assay [84], different concentrations of NaB were applied
to investigate its influence on the performance of the selected clone (C2C12 1B1
Cl.2). Therefore, cells were treatedwith NaB at 0.1mM, 1mM, 5mM and 10mM
24h prior to the uptake assay. However, NaB can indeed enhance E3S uptake
into the newly selected clone (Fig. 28 B). Highest uptake rates were observed at
5mM and 10mM. C2C12 wt cells and the previously selected clone C2C12 1B1
served as untreated negative or positive assay controls, respectively. As NaB
is toxic for C2C12 cells in the mM-range when treated for 48 h, all subsequent
investigations with C2C12 cells were conducted with 5mMNaB treatment 24 h
prior to the assay.
To characterize the new selected clone, a time course experimentwas performed,
where wild type and transfected cells were incubated with E3S (5µM) for 5, 10,
20, and 30min. Cells were treated with NaB (5mM) 24 h prior to the uptake
assay. The earlier selected clone C2C12 1B1 was used as positive control. As
shown in Fig. 29 the uptake reaches a plateau after approximately 20min for
C2C12 1B1 and for the new clone C2C12 1B1 Cl.2. The uptake after 20min was
about three fold higher for C2C12 1B1 Cl.2 and four fold higher for C2C12 1B1,
showing the functional expression of OATP1B1 in the new selected clone.
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Fig. 27: Uptake of [3H]-E3S into different clones of C2C12 cells expressing
OATP1B1 (A) or -1B3 (B)
Clones were selected by qRT-PCR where they showed high levels of
OATP1B1 or -1B3 mRNA. Green bars represent net-uptake and blues
bars represent transport specific uptake (subtraction of wild type
uptake). Each bar represents mean ± S.D. of three replicates.
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Fig. 28: Influence of sodium butyrate (NaB).
(A) Cell viability of C2C12 wild type cells after sodium butyrate (NaB)
treatment at different concentrations over 48h. Plate was read 5h
(green dots) and 6h (red dots) after alamarBlue R©addition. Each dot
represents mean ± S.D. of three replicates. (B) Transport of
[3H]-E3S (5µM) into C2C12 wild type cells and into the new
selected clone (C2C12 1B1 Cl.2). Cells were treated with (blue
bars) or without (green bars) NaB at different concentrations
24h prior the assay.
3.8.5 Western blot analysis of C2C12 cells expressing OATP1B1
To assess the expression of OATP1B1 at the protein level, Western blot assays
were performed. As earlier attempts failed to prove the presence of OATP1B1
protein in whole cell lysates, membrane fractions were isolated from whole cell
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Fig. 29: Uptake of [3H]-E3S into C2C12 cells
Different clones of C2C12 cells expressing OATP1B1 and control cells
were tested for E3S-uptake over time. Each data point represents
net-uptake values and shows mean ± S.D. of three replicates.
lysates to enrich proteins expressed in the cell membrane and to separate them
from the cytosolic fraction. Therefore, cells were harvested by scraping and
membranes were prepared as described in material and methods. The Western
blot analysis in Fig. 30 shows that OATP1B1 is not only expressed in the posi-
tive control CHO OATP1B1 (Fig. 30, lane 5) but also in the new clone and that
expression level is not depending on NaB treatment (Fig. 30, lanes 3- and 3+).
For the first time it was also possible to showOATP1B1 expression in the earlier
selected clone (C2C12 1B1), but NaB treatment reduced expression level in this
clone (Fig. 30, lanes 2- and 2+). The expected band is indicated by an arrow.
Fig. 30: Western blot analysis of membrane preparations
Total membrane fraction gained from C2C12 and CHO wild type and
transfected (OATP1B1) cells. Cells were treated with (+) or without (-)
NaB 24h prior harvesting. M: marker, 1: C2C12wt, 2: C2C12 1B1; 3:
C2C12 1B1 Cl.2, 4: CHOwt, 5: CHOOATP1B1
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3.9 Statin toxicity using the C2C12 1B1 Cl.2 cells
After identifying a clone functionally expressingOATP1B1 protein, cell viability
assays were performed again to elucidate whether toxicity after statin treatment
changes in the presence of a statin transporter and thus provide crucial hints on
the target site of statins. To additionally find out whether statin toxicity can
be reduced by inhibiting specifically OATPs/Oatps, an inhibitor was applied
additionally. De Graf et al. showed ICG mediated inhibition of E3S-uptake in
CHOOATP1B1 and -1B3, with IC50 values of 3.16µM and 2.35µM, respectively
[99]. Therefore, a concentration at least 3x times higher than these IC50 values
was chosen to test the hypothesis of reduced statin toxicity, whenOATPs/Oatps
are blocked. Briefly, C2C12 wt (wt) cells and C2C12 1B1 Cl.2 cells were treated
with or without ICG (10µM) one hour prior statin treatment. Cerivastatin, ator-
vastatin and lipophilic rosuvastatin and pravastatin were applied at increasing
concentrations. The results shown in Fig. 31 demonstrate that IC50 values differ
significantly only for cells treated with cerivastatin, when comparing ICG pre-
treated with untreated. Here IC50 values are increased for the transfected cell
lines as well as for the control cells indicating that cells pretreated with ICG are
less susceptible towards cerivastatin (Tab. 13). For pravastatin and rosuvastatin,
ICG did not significantly change IC50 values of both cell lines, when comparing
ICG-treated with ICG-untreated samples. For Atorvastatin IC50 values are de-
creased, when cells were pretreated with ICG. This effect was observed in both
cell lines.
Tab. 13: IC50 values of cell viability assay. Cells were treated with (+ICG) or
without (w/o ICG) ICG (10 µM) prior statin treatment.
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Fig. 31: Analysis of cell viability assays after statin treatment
C2C12 wild type (wt) and OATP1B1 (Cl.2) cells were exposed to
various concentrations of statins for 48h and treated with or without
ICG (10µM) 1h prior statin treatment. Cell viability was measured
with alamarBlue R©assay. Each data point represents the mean ±
S.D. of three replicates.
3.10 Statin-induced apoptosis in C2C12 cells
The new developed cell model was used to elucidate whether there is a differ-
ence in statin transporter dependent toxicity for C2C12 cells. Caspase-3 activity
is a hallmark of apoptosis. To investigate the ability of statins to induce apopto-
sis an assay was setup measuring caspase-3 activity after statin treatment. The
assay uses a caspase-3-specific substrates coupled to a fluorophore, which is
cleaved of by caspases-3 upon binding. The released fluorophore produces a
fluorescent signal which is directly proportional to caspase-3 activity. The first
step to setup this assay was to find out how long cells need to be treated with
statins before caspase-3 activity is measurable. Therefore, cells were treated
with cerivastatin (10µM) for 1 h, 2 h, 4 h and 6h. Cells were subsequently lysed
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and mixed with caspase-3-specific substrate Ac-DEVD-AMC. As this assay was
performed in 96-well plates suitable for fluorescent measurements, it was pos-
sible to reread the plates after a certain time to determine an appropriate sub-
strate conversion to ensure measurements are performed in the linear phase
and to obtain the best signal to noise ratio. Plates were read at 25min, 45min,
60min, 75min, 90min, 105min (Fig. 32). As caspase-3 is strongly activated after
more than 4 h, cells were treated for 6 h with increasing statin concentrations.
Staurosporin (300 nM) served as positive control, while negative controls were
treated with solvent (DMSO).
The results presented in Fig. 33 indicate that lipophilic statin cerivastatin and
simvastatin and, in part, hydrophilic rosuvastatin und pravastatin induce caspase-
3 activity in a dose dependentmanner in C2C12 cells transfectedwithOATP1B1,
where the strongest effect is seen in C2C12 1B1 cells. The highest dose of sim-
vastatin (1mM) induced caspase-3 activity in cells expressing OATP1B1 and in
wild type cells. The data for atorvastatin are not conclusive, as caspase-3 activ-
ity is slightly increased at 1µM and 100µM but not at 10µM in C2C12 1B1.
RESULTS 61
Fig. 32: Analysis of caspase-3 assay development
C2C12 wilt type cells (A) and C2C12 1B1 Cl.2 (B) where treated with
10µM cerivastatin for 1h, 2h, 4h, or 6h. After adding caspase-3
substrate to the lysed cells, fluorescent measurement was performed
after 25min, 45min, 60min, 75min, 90min, 105min.
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Fig. 33: Analysis of caspase-3 activity assay
C2C12 wild type cells (green), C2C12 1B1 cells (red) and C2C12 1B1
Cl.2 cells (blue) where treated for 6h with different statins at the
indicated concentrations. Staurosporin served as positive control.
Each bar represents mean ± S.D. of quadruplicates.
4 DISCUSSION
Today statins are key drugs for treating hypercholesterolemia and play an es-
sential role in the primary and secondary prevention of cardiovascular disease.
In the future the number of patients receiving statins is likely to increase as lat-
est research is investigating the potential of statins in breast cancer treatment
and as statins have been shown to reduce the risk to develop hepatocellular
cancer [100, 101]. Additionally, statins were recently shown to reduce cardio-
vascular events even in “patients” with “normal” LDL levels [102]. Although
statins have a favorable safety profile and have well documented benefits to
patients with cardiovascular disease, their adverse effects are neither negligible
nor do they have trivial consequences. Statins have several potential adverse
effects, mostly related to myopathies. In rare cases statin-induced myopathies
can lead to the dissolution of the skeletal muscle cells (rhabdomyolysis).
Therefore, understanding the etiology of statin-inducedmyopathies and the ex-
act mechanism behind is an area of increasing importance. Various in vivo and
in vitro models have shown that statins directly induce toxicity in muscle cells
[37, 40, 103–105]. The exact mechanism how statins induce toxicity in muscle
cells still needs to be clarified. It is currently not known to full detail whether
cytotoxic effects of statins on muscle cells originate at the plasma membrane
or are initiated intracellularly. Here, statin transporters might influence local
statin concentrations and play a crucial role in statin-induced myotoxicity [28].
Based on the present state of knowledge, this PhD thesis aimed to expand the
knowledge of how statins induce myopathies, by investigating the role of up-
take systems in statin-induced myotoxicity. To identify the relevance of uptake
transporters to the in vivo activity of statins, an in vitro tool was established
which allows studying the influence of uptake transporters on statin toxicity in
muscle cells. Therefore, skeletal muscle cells stably expressing the main uptake
transporters of statins into human liver were established. The skeletal muscle
63
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cell lines L6 (rat) and C2C12 (mouse) were transfected with the hepatocellu-
lar statin transporter OATP1B1 or OATP1B3. The transfected cells as well as
the non-muscle cell line CHO were then used to study the effect of statins on
cell viability and the potential to induce apoptosis. After the transfection, it
was possible to isolate a clone of the cell line C2C12 stably transfected with
OATP1B1 by functional testing (C2C12 1B1). This clone showed transport ac-
tivity of the OATP model substrate E3S (Fig. 11). Cell viability studies after
statin treatment revealed no difference in toxicity between the wild type and
transfected cells. To elucidate whether muscle cells are per se more sensitive
towards statins than non-muscle cells, the fibroblast cell lines CHO express-
ing OATP1B1, -1B3, or -2B1 and the wild type cells were compared with the
skeletal muscle cell lines C2C12 and L6. Results indicate that muscle cells are
indeed more susceptible towards statins as non-muscle cells. The expression
of the statin transporters OATP1B1, -1B3, or -2B1 in CHO cells had no influ-
ence on cytotoxicity after statin treatment. As it was not possible to demon-
strate the expression of the carrier at protein and RNA level, L6 and C2C12 cells
were transfected again, using a different vector. The new transfection yielded
a clone (C2C12 1B1, Cl.2), which is functional active, based on data of E3S up-
take (Fig. 29). It was also possible to demonstrate the expression of OATP1B1
at RNA and protein level. With the new clone it was possible to demonstrate
that certain statins induce apoptosis in a transporter dependent manner 33. The
decision to directly screen for functional active clones with the cellular uptake
assay was based on earlier experience with stable transfection experiments in
the lab [61, 80]. In this first round of transfection it was possible to identify a
clone showing consistently transport of the OATP model substrate E3S (C2C12
1B1) and the hydrophilic pravastatin, which exceeded uptake into wild type
cells by about factor five (Fig. 29, Fig. 14). To further characterize the selected
clone C2C12 1B1, it was tried to localize OATP1B1 at the subcellular level us-
ing CLSM. The signal from C2C12 1B1 samples was distributed all over the cell,
while the CHOOATP1B1 sample showed a clear localization of OATP1B1 to the
plasma membrane (Fig. 18). One could now speculate whether this signal is the
result of mistargeted proteins, which are dispersed in intracellular organells, or
whether it represents background due to the increased laser power. Although
different antibodies were tested and several parameters during sample prepa-
ration were changed, it was not possible to definitely localize OATP1B1 to the
plasma membrane and thus demonstrating its proper integration in the plasma
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membrane. This is in contradiction to the results from transport experiments.
Using Western blotting and qRT-PCR analysis, it was also not possible to show
the expression of OATP1B1. It was suggested, that part of the translated pro-
tein at the C-terminal end is missing, which maybe has no influence on the
functionality of OATP1B1. This hypothesis could be excluded as different an-
tibodies were tested, targeting the middle region or the N-terminal region of
OATP1B1. In these tests it was also not possible to demonstrate the expression
of OATP1B1. These data are very conflicting as on the one hand it was possible
to reproducibly show the expression of a transporter at a functional level and on
the other hand it was not possible to demonstrate the expression of OATP1B1
on RNA or protein level. One can only speculate about the reason of this phe-
nomenon. During transfection the plasmid DNA gets integrated randomly into
the genome of the host cell. This integration could lead to the disruption of
repressor elements regulating the expression of endogenous uptake systems,
which in turn leads to an enhanced expression of transporters responsible for
the uptake of the tested substrates. It might therefore be possible that C2C12 en-
dogenously expresses Oatps, which became upregulated somehow through the
process of transfection. Slco1b2 and Slco2b1 are known orthologues of the hu-
man OATPs OATP1B1 and OATP2B1, respectively. At least OATP2B1 is known
to be expressed at the sarcolemmal membrane of human skeletal muscle fibers
[53]. Proteins of Slco1b2 and Slco2b1 are not expressed in wild type C2C12 and
L6 cells, which were tested during this work using qRT-PCR (data not shown).
Additionally, our data show that C2C12 cells take up statins to a larger extent
compared to CHO cells, which indicates that the barrier function in muscle cells
is different from non-muscle cells (Fig. 14). These data are in accordance with
the data of the cell viability test, where CHO and muscle cells were compared
after statin treatment, demonstrating a higher susceptibility of muscle cells to-
wards statins compared to the non-muscle fibroblasts (Fig. 5).
Although several studies were performed with the initially selected clone, L6
andC2C12 cells were transfected again using a different vector previously shown
toworkwith C2C12 and L6 cells, namely pcDNA3.1. Another reason for switch-
ing the vector was that pcDNA3.1 contains a polyadenylation site, which im-
proves mRNA stability (Fig. 3). The previously used vector pIRESneo2 con-
tained a synthetic intron to stabilize the mRNA [95]. Having learned that high
functionality does not directly mean high protein expression, the strategy to
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successfully find a clone expressing OATP1B1 or -1B3 and simultaneously be-
ing highly active in the transport assay was adapted. For the new transfections,
functional screening was paralleled with gene expression analysis using qRT-
PCR. This new strategy enabled the identification of a functional active clone,
which also shows expression of the respective mRNA (Fig. 26). With a new es-
tablished method it was additionally possible to demonstrate the expression of
OATP1B1 on protein level, not only in the new clone C2C12 1B1 Cl.2, but also
for the first time in the earlier selected clone C2C12 1B1 (Fig. 30). Reason for this
might be the general low expression level of this transporter after transfection
in this cell system.
The previously performed toxicity studies with statins where now repeated
with the new clone C2C12 1B1 Cl.2. To inhibit OATP1B1, ES3 sulfate was re-
placed by ICG, which was previously shown to act as inhibitor of OATP1B1
but not as substrate [95]. The results obtained in this test (Fig. 31) are similar
to the previously obtained results with the earlier clone (Fig. 16, Fig. 17). These
tests revealed that there is no difference in toxicity when comparing C2C12 1B1
Cl.2 and wild type cells. One possible explanation could be that the time point
(48h) of measuring the cell viability is too late. The cell viability assay mea-
sures the reducing power of living cells and to clearly recognize differences in
treated and control groups, cells need to be treated for at least 48h with a toxin.
As transport rates of OATPs are up to several nmol/mg protein·min−1 and as
C2C12 wild type cells probably also express Oatps, chances are high that statins
get inside the cell and reach steady state already after a few hours. Addition-
ally, chances are quite high for lipophilic statins to penetrate the plasma mem-
brane during this long lapse of time and induce toxicity inside the cell. On the
other hand our data show at least for cerivastatin that toxicity is reduced, when
OATPs/Oatps are blocked with ICG, supporting the concept that statins need
to be taken up in a transporter dependent manner and induce toxicity from in-
side the cell. Atorvastatin, rosuvastatin and pravastatin should have had been
tested at higher concentrations, which was not possible due to their solubility
limit. As the cell viability assay is looking at a very late stage of cell death, an
assay was setup to investigate an early marker of apoptosis after statin treat-
ment. Activation of caspase-3 is a hallmark of apoptosis and is induced already
after several hours of treatment with an apoptotic toxin [106, 107]. Cerivastatin,
simvastatin and rosuvastatin nicely show a concentration dependent induction
of caspase-3 in C2C12 1B1 cells and not in the control cells, which shows the
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necessity of a transport system to induce apoptosis. Studies investigating the
potential of statins to induce caspase-8 and caspase-9 in C2C12 1B1 cells also
suggest a role of transport proteins, i.e. intracellular action of the statins, but
data were not reproducibly conclusive (data not shown). Taken together, these
results indicate that myotoxicity is induced by intracellular toxicity of statins.
Interestingly it was not possible to show the induction of caspase-3 in pravas-
tatin treated cells. In the assays used in this work, pravastatin showed only
slight cell toxicity and caspase-3 activation at the highest tested concentration
(1mM) in C2C12 cells. This is not in accordance with clinically observed mus-
cle toxicities induced by pravastatin, which has a similar incidence as atorvas-
tatin and simvastatin [108]. Reason for this could be that pravastatin has a
different mechanism to induce toxicity and that the established in vitro sys-
tem is lacking the toxicity-target of pravastatin, which is only apparent in the
in vivo situation. Another explanation for this phenomenon could be that a
metabolite of pravastatin is the elicitor and that C2C12 cells are an inappro-
priate test system to investigate toxicity for this particular statin. The effect of
medium pH on the statin transport has been investigated only to a minor ex-
tent. It is well established that OATPs generally exhibit higher transport rates
under low extracellular pH [109, 110]. The group of Iseki et. al demonstrated
an increased uptake of rosuvastatin under acidic medium conditions using rat
L6 and human RD cells [111]. As the interstitial pH of skeletal muscle dur-
ing exercises is decreased [111] the question came up whether transport rates
of statins change under acidic conditions. Therefore, the relationship between
pravastatin-, cerivastatin- and simvastatin-transport and medium pH was ex-
amined. The uptake under acidic conditions (pH 6.5) revealed that transport
rates were significantly increased only for cerivastatin compared to the physi-
ological conditions (pH 7.4). For pravastatin, there was only a trend to higher
uptake rates under acidic conditions. These results may provide an indication
why muscle tissue is at higher risk to show toxicity symptoms after statin treat-
ment.
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Conclusion
In conclusion, the results of this work contribute to understanding the mecha-
nism of how statins induce myotoxicity. The role of an uptake system in statin-
induced rhabdomyolysis cannot be neglected. Although the exact uptake sys-
tem in skeletal muscle cells responsible for statin uptake could not be identified,
the results of this work indicate that statins need to be taken up into the cell to
induce cell toxicity and the cytotoxic action of statins from the outside of cells
does not explain completely statin myotoxicity. An inhibition of this uptake
system can reduce toxicity to a certain degree. During the work of this thesis a
model system was established, allowing investigations of compounds being an
OATP substrate and their influence on myoblasts.
Outlook
HMG-CoA reductase acts early in the mevalonate pathway and thus inhibition
also interfere with the synthesis of many non-steroidal isoprenoid molecules.
Therefore, it is preferable to prevent the cholesterol biosynthesis by targeting
an enzyme, which lies downstream of farnesyl pyrophosphate in the choles-
terol biosynthesis pathway, without interrupting the biosynthesis of essential
physiological components, such as ubiquinone and dolichol. Investigations to
find other drugs to treat hypercholesterolemia which act further downstream
in cholesterol synthesis looked promising at the beginning. Takeda pharma-
ceutical tried to inhibit squalene synthase (Fig. 1), not to disturb the mevalonate
pathway, with lapaquistat acetate. In 2008 the development of this compound
was discontinued “. . . based on judgment that the profile of the compound is not su-
perior to existing marketed drugs from both efficacy and safety viewpoints.” [112]. An-
other promising candidate is zaragozic acid, which is currently discussed and
reviewed [113, 114]. Zaragozic acids are a family of fungal metabolites and act
as inhibitors of squalene synthase. Interestingly, family members of zaragozic
acid have been identified as ras farnesyl transferase and geranylgeranyl trans-
ferases inhibitors [115], which consequently would inhibit ubiquinone and do-
lichol production (Fig. 1). In 2013 a Japanese group published the structure of
a lead compound acting as squalene synthase inhibitor and demonstrated their
in vivo efficacy and liver selectivity [116]. Nevertheless, no compound focusing
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on the inhibition of the squalene-cholesterol branch has done it to the market so
far, but recent publications look promising to find a new class of pharmaceuti-
cals to treat hypercholesterolemia.
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